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Introduction

In recent years, cannabis products that have not received approval
from the U.S. Food and Drug Administration (FDA) have become
increasingly popular. Non-FDA-approved products containing delta-9tetrahydrocannabinol (THC) and cannabidiol (CBD), such as tinctures,
gummies and other edibles, lotions, pills, and vaping oils and inhalation
products, are sold everywhere from high-end beauty stores to local gas
stations. The growing availability of these products is largely due to
states’ concerted efforts to enact laws legalizing non-FDA-approved
cannabis products.1 These laws create unique challenges for employers,
including workplace safety issues and personnel decisions, including
hiring, firing, and disciplinary actions. Employers must also wrestle
with the fact that their employees may use cannabis for medical reasons,
even though the cannabis products that their employees use have not
undergone the FDA’s rigorous review and approval process, and
therefore, have unknown safety and efficacy profiles, as well as
unpredictable composition and quality.
Despite the recent passage of the Agriculture Improvement Act of
2018 (“the Farm Bill”), which was intended to carve out hemp-derived
products from the definition of “marijuana” under the federal Controlled
Substances Act (CSA),2 most non-FDA-approved cannabis products
remain illegal under the CSA and the Food, Drug, and Cosmetics Act
(FDCA).3 Marijuana is still a Schedule I substance under the CSA,
meaning that it has no currently accepted medical use and has a high
Additionally, non-FDA-approved cannabis
potential for abuse.4
products, including CBD products, are often marketed for therapeutic
purposes in violation of the FDCA.5 The FDCA only permits
1 See State Medical Marijuana Laws, NAT’L CONFERENCE OF STATE LEGISLATURES, (Oct. 12,
2020), https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.
2 The Agriculture Improvement Act of 2018 defines “hemp” as “the plant Cannabis
sativa L. and any part of that plant, including the seeds thereof and all derivatives,
extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or
not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on
a dry weight basis.” 7 U.S.C. § 1639o(1).
3 21 U.S.C. § 812 Schedule 1 (c)(17) (setting forth Schedule 1 controlled
substances); 21 C.F.R. §§ 1308.11(d)(23), (58); 21 U.S.C. § 331(a) (stating that an
unapproved new drug cannot be sold in interstate commerce under the FDCA). Illegality
under the FDCA stems from two different theories. Non-hemp products are illegal per se
in foods, dietary supplements, and drugs. All cannabis, including hemp products, that
make therapeutic claims are illegal unless they are FDA-approved drugs.
4 21 U.S.C. § 812(b)(1).
5 21 U.S.C. §§ 321(g)(1), 331 (a), 352(a); see, e.g., FDA Warns 15 Companies for
Illegal Selling Various Products Containing Cannabidiol as Agency Details Safety Concerns,
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manufacturers of FDA-approved drugs to make therapeutic claims
about their products.6 Currently, the FDA has only approved four
prescription drugs containing cannabis – one cannabis-derived and
three cannabis-related drugs.7 These drugs include one product
containing cannabis plant-derived CBD as its active ingredient, two
products that include the active ingredient dronabinol (i.e., a synthetic
THC), and one product containing the active ingredient nabilone (i.e., a
synthetic product with a chemical structure similar to THC).8 The FDAapproved CBD product is specifically indicated for the treatment of
seizures associated with three rare and severe forms of epilepsy,
Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis
Complex; dronabinol is indicated for the treatment of anorexia
associated with weight loss in patients with AIDS; and both dronabinol
and nabilone are indicated for nausea and vomiting associated with
cancer chemotherapy.9 Yet, manufacturers of non-FDA-approved
cannabis products have made unsubstantiated claims that their
products can be used to prevent, diagnose, mitigate, treat, or cure
several medical conditions, including: Alzheimer’s Disease, autism,
cancer, diabetes, heart disease, kidney disease, liver disease, opioid use
disorder, Parkinson’s Disease, and most recently, COVID-19.10
Additionally, manufacturers of non-FDA-approved cannabis
products have marketed their products as dietary supplements or
FDA (Nov. 25, 2019), https://www.fda.gov/news-events/press-announcements/fdawarns-15-companies-illegally-selling-various-products-containing-cannabidiolagency-details [hereinafter FDA Warns 15 Companies].
6 21 U.S.C. §§ 321(g)(1), 331 (a), 352(a).
7 FDA Regulation of Cannabis and Cannabis‐Derived Products, Including Cannabidiol
(CBD), FDA (Oct. 1, 2020), https://www.fda.gov/news-events/public-health-focus/fdaregulation-cannabis-and-cannabis-derived-products-including-cannabidiolcbd#farmbill [hereinafter FDA Regulation of CBD].
8 Epidiolex
Label,
Greenwich
Biosciences,
https://www.epidiolex.com/sites/default/files/pdfs/1120/EPX-036451120_EPIDIOLEX_(cannabidiol)_USPI.pdf#page=9; Marinol Label, FDA (Revised Aug.
2017),
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf;
Syndros
Label,
FDA
(Revised
July
2016),
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205525s000lbl.pdf;
Cesamet
NDA,
FDA
(Revised
May
2006)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf.
9 Id.
10 See Warning Letter: Homero Corp DBA Natures CBD Oil Distribution, FDA (Apr. 20,
2020),
https://www.fda.gov/inspections-compliance-enforcement-and-criminalinvestigations/warning-letters/homero-corp-dba-natures-cbd-oil-distribution605222-04202020; Warning Letter: CBD Gaze, FDA (May 26, 2020),
https://www.fda.gov/inspections-compliance-enforcement-and-criminalinvestigations/warning-letters/cbd-gaze-607299-05262020.
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food.11 Yet, the FDA has clearly stated that it is illegal to market such
non-FDA approved cannabis products by adding them to food or
labeling them as dietary supplements.12 Nonetheless, FDA is “concerned
at the proliferation of such products.”13 In light of the lack of regulatory
oversight and enforcement against illegal drug products, employees
who use such products could be at risk of ingesting high concentrations
of THC or contaminated and unsafe substances, including undisclosed
pesticides, heavy metals, and controlled substances, such as K2/spice.14
Use of these products creates particularly unique challenges for
employers given that THC can cause impairment.15
Arguably there are minimal differences between medical and
recreational cannabis beyond their “intent of use” and cost. Yet, at least
six states have introduced legislation to require health plans and
workers’ compensation programs to cover non-FDA-approved cannabis
products for medical purposes, despite the lack of safety and efficacy
requirements.16 Such legislation directly conflicts with federal laws,
such as the CSA and the FDCA, poses health risks to employees, and
increases risk of liability for employers. As such, states should not enact
these mandates.
Part II of this Article defines key terminology and provides an
overview of relevant federal laws, such as the Farm Bill of 2018, the CSA,

11 FDA Regulation of Dietary Supplement & Conventional Food Products Containing
Cannabis
and
Cannabis‐Derived
Compounds,
FDA,
https://www.fda.gov/media/131878/download (last visited Nov. 3, 2020).
12 What You Need to Know (And What We’re Working to Find Out) About Products
Containing Cannabis or Cannabis‐Derived Compounds, Including CBD, FDA,
https://www.fda.gov/consumers/consumer-updates/what-you-need-know-andwhat-were-working-find-out-about-products-containing-cannabis-orcannabis#:~:text=The%20FDA%20has%20approved%20only,it%20as%20a%20dieta
ry%20supplement (last updated Mar. 5, 2020) [hereinafter What You Need to Know (And
What We’re Working to Find Out)]. But note that the FDA considers certain foods
containing hemp and hemp seed-derived food ingredients to be “generally recognized
as safe” or GRAS. FDA Responds to Three GRAS Notices for Hemp Seed‐Derived Ingredients
for Use in Human Food, FDA, (Dec. 20, 2018), https://www.fda.gov/food/cfsanconstituent-updates/fda-responds-three-gras-notices-hemp-seed-derived-ingredientsuse-human-food.
13 FDA Regulation of CBD, supra note 7.
14 Lisa Fletcher, The Risk of Contaminants and False Labeling in the Exploding CBD
Industry, WJLA (May 15, 2019), https://wjla.com/features/7-on-your-side/the-risk-ofcontaminants-and-false-labeling-in-the-exploding-cbd-industry.
15 See Report to the U.S. House Committee on Appropriations and the U.S. Senate
Committee on Appropriations, Sampling Study of the Current Cannabidiol Marketplace to
Determine the Extent that Products Are Mislabeled or Adulterated, FDA (2020),
https://hempindustrydaily.com/wp-content/uploads/2020/07/CBD-MarketplaceSampling_RTC_FY20_Final.pdf.
16 See infra Part III.A.
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FDCA, and state laws governing the use of cannabis products. Part III
analyzes proposed legislation that would mandate coverage of nonFDA-approved cannabis products and how that legislation may directly
conflict with various federal laws, creating the potential for employer
liability. Part IV provides recommendations for state legislators and
employers.

II.

Background

The federal and some state governments have enacted legislation
with the intent to legalize non-FDA-approved cannabis products,
including CBD products. There are, however, other federal laws that
directly conflict with these state legalization efforts. Additionally,
products currently sold to the public oftentimes do not comply with the
federal or state laws that intended to legalize such products. This
section defines key terminology and summarizes those relevant laws.
A. TERMINOLOGY
The terms “cannabis” and “marijuana” are often used
interchangeably, however, they do not have the same meaning. 17
“Cannabis” refers to “a plant of the Cannabaceae family and contains
more than eighty biologically active chemical compounds,” with the
most commonly known compounds being THC and CBD. 18 Under
federal law, the term “marijuana” (or “marihuana”) refers to “all parts of
the plant Cannabis sativa L., whether growing or not; the seeds thereof;
the resin extracted from any part of such plant; and every compound,
manufacture, salt, derivative, mixture, or preparation of such plant, its
seeds or resin.” 19 Additionally, according to a recent interim final rule
from the U.S. Drug Enforcement Administration (“DEA”), “marihuana
extract” is defined as “an extract containing one or more cannabinoids
that has been derived from any plant of the genus Cannabis, containing
greater than 0.3 percent delta-9-tetrahydrocannabinol on a dry weight
basis, other than the separated resin (whether crude or purified)
obtained from the plant.”20 “Marihuana” does not include “hemp” as that
term is defined or:
17

Cannabis (Marijuana) and Cannabinoids: What You Need To Know, NIH NAT’L CTR.
https://www.nccih.nih.gov/health/cannabismarijuana-and-cannabinoids-what-you-need-to-know (last updated Nov. 2019).
18 FDA Regulation of CBD, supra note 7.
19 21 U.S.C. § 802(16)(A).
20 Implementation of the Agriculture Improvement Act of 2018, 85 Fed. Reg. 51639,
51641–42 (Aug. 21, 2020) (interim final rule) (emphasis added); but see, Brief of
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the mature stalks of such plant, fiber produced from such
stalks, oil or cake made from the seeds of such plant, any other
compound, manufacture, salt, derivative, mixture, or
preparation of such mature stalks (except the resin extracted
therefrom), fiber, oil, or cake, or the sterilized seed of such
plant which is incapable of germination.21
“Hemp” is defined as “the plant Cannabis sativa L. and any part of
that plant, including the seeds thereof and all derivatives, extracts,
cannabinoids, isomers, acids, salts, and salts of isomers, whether
growing or not, with a delta-9 tetrahydrocannabinol concentration of
not more than 0.3 percent on a dry weight basis.”22 Hemp is an industrial
plant once cultivated exclusively for its fiber and edible seeds.23 While
hemp is a variety of the cannabis plant, hemp varieties are lower in THC
content than marijuana plants, as required by U.S. law.24
THC is the main psychoactive constituent of marijuana and is
primarily responsible for the intoxicating and impairing effects that
marijuana has on a person’s mental state.25 Cannabinoids are “[a]ny of
the various naturally occurring, biologically active chemical
constituents of hemp or cannabis, including some that possess
psychoactive properties,” such as THC.26 CBD is a non-psychogenic
cannabinoid derived from marijuana or synthesized.27
In this Article, the term “non-FDA-approved cannabis products” is
used as a catchall term. It includes all products that are illegal under the
CSA (i.e., marijuana, marijuana extract, and THC) and illegal under the
FDCA (i.e., non-FDA-approved products regardless of whether they are
derived from hemp or marijuana, or in other words, regardless of
whether they contain less than 0.3 percent THC). The term does not
Petitioner at 5, Hemp Indus. Ass’n v. DEA, No. 20-1376 (D.C. Cir. Sept. 18, 2020)
(challenging the legality of the Interim Final Rule).
21 21 U.S.C. § 802(16)(B).
22 7 U.S.C. § 1639o(1) (emphasis added).
23 Dana Sullivan Kilroy, Speaking the Endocannabinoid System: A Glossary of Terms
Used to Describe Marijuana, Cannabidiol, the Endocannabinoid System, and Cannabis,
EVERYDAY HEALTH (Nov. 6, 2019), https://www.everydayhealth.com/marijuana/cbdoil/glossary/.
24 Id.
25 Cannabis (Marijuana) and Cannabinoids: What You Need To Know, supra note 17.
26 Kilroy, supra note 24.
27 Common Terminology & Glossary, THE COLLABORATIVE FOR CBD SCI. & SAFETY,
https://a2890a0f-5011-4a6c-a93d804dc45494d5.usrfiles.com/ugd/a2890a_b3d21d5fcebb49669a5191ef4dcf0a2a.pdf
(last visited Nov. 3, 2020).
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include food products containing hemp that the FDA has deemed legal
(i.e., certain foods containing hemp and hemp seed-derived food
ingredients that the FDA consider to be “generally recognized as safe”
or “GRAS”).28 The term also does not include CBD-containing cosmetics,
which the FDA does not prohibit outright, unless such products make
improper therapeutic claims.29
B. THE CSA
Enacted in 1970, the CSA provides the DEA with regulatory
authority over controlled substances, including the authority over the
manner in which controlled substances are imported, manufactured,
distributed, possessed, and used.30 Controlled substances are drugs or
other substances with abuse potential.31 The DEA categorizes a
controlled substance within five schedules based on their medical
effectiveness and abuse potential.32
Schedule I is reserved for substances with (1) the highest potential
for abuse, (2) no currently accepted medical use in the U.S., and (3) a
lack of accepted safe use under medical supervision.33 Under the CSA, it
is a crime to “knowingly or intentionally . . . possess” and to “knowingly
or intentionally . . . manufacture, distribute, or dispense, or possess with
the intent to manufacture, distribute, or dispense” a Schedule I
substance.34 Marijuana is regulated as a Schedule I substance.35 THC
(except for THC in hemp) is also a Schedule I substance.36 The CSA
prohibits possession and distribution of non-FDA-approved marijuana
even for medical use, regardless of whether a state has enacted a law to
allow such use.37 The CSA, however, does permit marijuana to be used
in research by properly-licensed researchers.38

28 FDA Responds to Three GRAS Notices for Hemp Seed‐Derived Ingredients for Use in
Human Food, supra note 12.
29 FDA Regulation of CBD, supra note 7.
30 See 21 U.S.C. §§ 801, 811.
31 21 U.S.C. §§ 802(6), 811(c).
32 See 21 U.S.C. §§ 811, 812.
33 21 U.S.C. § 812(b)(1).
34 21 U.S.C. § 841(a)(1).
35 21 U.S.C. § 812(c)(10); 21 C.F.R. §§ 1308.11(d)(23), (58).
36 21 U.S.C. § 812 Schedule 1(c)(17).
37 See Gonzales v. Raich, 545 U.S. 1, 29 (2005).
38 21 U.S.C. § 822(b); Controls to Enhance the Cultivation of Marihuana for Research
in the United States, 85 Fed. Reg. 82333, 82338 (Dec. 18, 2020) (Final Rule).
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C. THE FARM BILL
In December 2018, Congress passed the Farm Bill, which among
other things, made changes related to the production and marketing of
hemp.39 As noted above, the Farm Bill defined “hemp” as “the plant
Cannabis sativa L. and any part of that plant, including the seeds thereof
and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts
of isomers, whether growing or not, with a delta-9
tetrahydrocannabinol concentration of not more than 0.3 percent on a
dry weight basis.”40 It also amended the CSA by removing hemp from
the CSA’s definition of marijuana and the Schedule I listing of THC. 41 As
a result, hemp-derived products (including hemp-derived CBD
products) containing less than 0.3 percent THC that were produced with
less than 0.3 percent THC extract are no longer considered controlled
substances under federal law.42 Conversely, any marijuana products
with levels of THC above the 0.3 percent cut-off are not considered to be
“hemp products” and are, therefore, still regulated as Schedule I
controlled substances under the CSA.43
On August 26, 2019, the DEA announced that it would no longer
require registration to grow, research, or manufacture hemp because
hemp was “not a controlled substance.”44 On August 21, 2020, the DEA
issued an interim final rule (“IFR”), which was intended to codify
regulations required by the Farm Bill.45 The DEA stated that the IFR
39

FDA Regulation of CBD, supra note 7.
FDA Regulation of CBD, supra note 7 (emphasis added); cf. Agricultural Act of 2014,
Pub. L. No. 113-79, § 7606(b)(2), 128 Stat. 912-13 (2014). Congress enacted the
Agricultural Act of 2014 (2014 Farm Bill), which initially defined “industrial hemp” as
“the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a
delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry
weight basis.” The 2014 Farm Bill allowed institutes of higher education and state
departments of agriculture to grow and cultivate industrial hemp for research in limited
circumstances. The 2014 Farm Bill did not, however, remove hemp from the schedules
of controlled substances under the CSA.
41 CONGRESSIONAL RESEARCH SERVICE, R44742, Defining Hemp: A Fact Sheet,
https://fas.org/sgp/crs/misc/R44742.pdf (updated Mar. 22, 2019).
42 FDA Regulation of CBD, supra note 7.
43 FDA Regulation of CBD, supra note 7.
44 DEA Announces Steps Necessary to Improve Access to Marijuana Research, DEA
(Aug. 26, 2019), https://www.dea.gov/press-releases/2019/08/26/dea-announcessteps-necessary-improve-access-marijuana-research.
45 The regulations state that the definition of THC does not include “any material,
compound, mixture, or preparation that falls within the definition of hemp,” and it stated
that the definition of “marihuana extract” is limited to extracts “containing greater than
0.3 percent delta-9-tetrahydrocannabinol on a dry weight basis.” The IFR also removed
FDA-approved products containing CBD from schedule V, among other changes.
Implementation of the Agriculture Improvement Act of 2018, 85 Fed. Reg. 51639–40
(Aug. 21, 2020) (interim final rule).
40
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“merely conforms DEA’s regulations to the statutory amendments to the
CSA that have already taken effect.”46 But, the IFR defined “marihuana
extract” as extracts “containing greater than 0.3 percent delta-9tetrahydrocannabinol on a dry weight basis.”47 This means that if a
hemp product contains intermediate extracts of 0.3 percent THC at
some point during the manufacturing process, then it is still considered
a Schedule I controlled substance, even if the finished product has less
than 0.3 percent THC.48 In response, Hemp Industries Association and
RE Botanicals Association filed suit against the DEA in the U.S. Court of
Appeals for the D.C. Circuit to challenge the rule.49 The case is still
pending. The DEA, for now, will not regulate hemp-derived products
containing less than 0.3 percent THC of a dry weight basis and that were
produced using intermediate extracts containing less than 0.3 percent
THC. The DEA will, however, continue to regulate marijuana and
marijuana extract products containing more than 0.3 percent THC on a
dry weight basis as illicit Schedule I substances, at least while the IFR
remains in place.
At the same time, the Farm Bill “explicitly preserved FDA’s
authority to regulate products containing cannabis or cannabis-derived
compounds under the [FDCA] and section 351 of the Public Health
Service Act (PHS Act).”50 According to the FDA, all cannabis and
cannabis-derived products are “subject to the same authorities and
requirements as any other FDA-regulated products[.]”51
D. THE FOOD, DRUG, AND COSMETICS ACT
Originally enacted in 1938, the FDCA provides the FDA with the
authority to regulate food, drug, and cosmetic products, by, among other
things, creating regulatory pathways for products and enforcing
consumer protection provisions.52 Under the act, the FDA defines a
prescription drug as “a substance intended for use in the diagnosis, cure,
46

Id.
Id.
48 Id. at 51640–41.
49 Brief of Petitioner at 5, Hemp Indus. Ass’n v. DEA, No. 20-1376 (D.C. Cir. Sept. 18,
2020). Petitioners argue that 1) the DEA promulgated the IRF without complying with
the proper procedure required by law; 2) the rule exceeds statutory jurisdiction,
authority, or limitations; and 3) the IFR is arbitrary, capricious, an abuse of discretion,
or otherwise not in accordance with law in violation of the Administrative Procedures
Act. Id.
50 FDA Regulation of CBD, supra note 7.
51 FDA Regulation of CBD, supra note 7.
52 How Did the Federal Food, Drug, and Cosmetic Act Come About?, FDA,
https://www.fda.gov/about-fda/fda-basics/how-did-federal-food-drug-and-cosmeticact-come-about (last updated Mar. 28, 2018).
47
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mitigation, treatment, or prevention of disease” that is prescribed by a
health care practitioner and regulated by the FDA.53 Prior to marketing,
a prescription drug must meet the FDA’s standards for safety and
efficacy.54 Drugs must also uniformly meet standards regarding quality,
purity, and dosage.55 The FDA applies rigorous standards and requires
substantial scientific evidence to prove a product meets the safety and
efficacy requirements for its intended use before it is approved as a
drug.56 A drug without the FDA’s prior approval is deemed a “new drug”
under the FDCA, and it cannot be introduced, distributed, or sold in
interstate commerce.57
In contrast, the FDCA defines a dietary supplement as a product
that is intended to supplement a diet, contains one or more dietary
ingredient (e.g., vitamins, minerals, herbs), and is intended to be taken
orally.58 The FDA does not review dietary supplements for safety or
efficacy before they are marketed in the U.S. unless they contain new
dietary ingredients.59 Additionally, while the FDA has established good
manufacturing practices (GMPs) that manufacturers must comply with
to help ensure the identity, purity, strength, and composition of their
products, the FDA does not have a regulatory pathway ensuring the
safety and efficacy of dietary supplements in the U.S. through a preapproval process as is applicable to drugs.60
Moreover, dietary supplements are intended to support a
consumer’s diet rather than treat a patient’s medical condition.61 If a
53 21 U.S.C.S. § 321(g)(1)(B); Prescription Drugs and Over‐the‐Counter (OTC) Drugs:
Questions
and
Answers,
FDA,
https://www.fda.gov/drugs/questionsanswers/prescription-drugs-and-over-counter-otc-drugs-questions-and-answers (last
updated Nov. 13, 2017).
54 21 U.S.C.S. § 321(p)(1).
55 21 C.F.R. § 211.22(c).
56 21 U.S.C. § 355(d) (defining “substantial evidence” as that which generally
consists of data from “adequate and well-controlled” clinical trials); 21 C.F.R. § 314.126;
see also 21 U.S.C. § 393(b)(2)(B); FDA v. Brown & Williamson Tobacco Corp., 529 U.S.
120, 133 (2000).
57 21 U.S.C. § 331.
58 Questions
and
Answers
on
Dietary
Supplements,
FDA,
https://www.fda.gov/food/information-consumers-using-dietarysupplements/questions-and-answers-dietary-supplements (last updated July 22,
2019).
59 What You Need to Know (And What We’re Working to Find Out), supra note 12; 21
U.S.C. § 350b(d). The FDCA defines a “new dietary ingredient” as “a dietary ingredient
that was not marketed in the United States before October 15, 1994 and does not include
any dietary ingredient which was marketed in the United States before October 15,
1994.” 21 U.S.C. § 350b(d).
60 What You Need to Know (And What We’re Working to Find Out), supra note 12;
Questions and Answers on Dietary Supplements, supra note 58.
61 21 U.S.C. § 321(ff).
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dietary supplement manufacturer makes therapeutic claims about its
product, then the product would be an illegal new and misbranded drug,
in violation of the FDCA.62 Such products would be considered “drugs”
rather than “supplements” under the FDCA because they are intended
for use in the diagnosis, cure, mitigation, treatment, or prevention of
disease, or intended to affect the structure or any function of the body.63
Yet, given that supplements are not FDA-approved, supplements with
therapeutic claims are not generally recognized as safe and effective for
the claimed uses.64 Such supplements, therefore, are new drugs under
the FDCA which cannot be introduced into interstate commerce until
they receive FDA approval.65
These provisions notwithstanding, marketers frequently claim that
their cannabis and cannabis-derived products treat serious medical
conditions even though they have not been approved by the FDA and
there is no substantial evidence of effectiveness or safety.66 Yet, the FDA
has not approved marijuana as a “drug” for therapeutic use under the
FDCA. As mentioned, the agency has only approved one cannabisderived and three cannabis-related products. The FDA has also stated
that irrespective of claims, CBD and THC are only permissible in FDAapproved drugs and are not permissible ingredients in foods or dietary
supplements.67
In other words, the FDA authorized the study of, and approved the
use of, a prescription drug containing CBD or THC prior to the marketing
of CBD and THC as a dietary supplement or an ingredient in food.68

62

21 U.S.C. § 352(f)(1).
21 U.S.C. § 321(g).
64 21 U.S.C. § 321(ff)(3)(B).
65 21 U.S.C. § 331.
66 FDA Regulation of CBD, supra note 7.
67 Statement from FDA Commissioner Scott Gottlieb M.D., on Signing of the Agriculture
Improvement Act and the Agency’s Regulation of Products Containing Cannabis and
Cannabis‐Derived Compounds, FDA (Dec. 20, 2018), https://www.fda.gov/newsevents/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signingagriculture-improvement-act-and-agencys (“It is unlawful under the [FDCA] to
introduce food containing added CBD or THC into interstate commerce, or to market
CBD or THC products as, or in, dietary supplements, regardless of whether the
substances are hemp-derived. This is because both CBD and THC are active ingredients
in FDA-approved drugs and were the subject of substantial clinical investigations before
they were marketed as foods or dietary supplements. Under the [FDCA], it’s illegal to
introduce drug ingredients like these into the food supply, or to market them as dietary
supplements.”) [hereinafter Statement from FDA Commissioner Gottlieb].
68 As of November 11, 2020, the FDA has approved one CBD drug product
(Epidiolex). Orange Book: Approved Drug Products with Therapeutic Equivalence
Evaluations, FDA, https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm (last
visited March 13, 2021) (search “cannabidiol”).
63
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Therefore, no food or dietary supplement may contain CBD or THC; they
are excluded from the FDCA’s definition of dietary supplement,69 and
they are not permissible in foods because they are not GRAS or an
approved additive.70 CBD and THC cannot, therefore, be introduced into
interstate commerce.71
The FDA has stated that it has the authority to issue a regulation
allowing the use of a pharmaceutical ingredient in a food or dietary
supplement, and the agency is currently in the process of evaluating
what such a regulatory pathway might look like.72 Until it creates one,
however, the FDA will continue to deem the marketing of such products
to be illegal.73
E. STATE LAW
While marijuana remains an illegal Schedule I substance under
federal law, as of the end of 2019, forty-eight states have laws that
decriminalize or allow the use of non-FDA-approved cannabis products
under some circumstances.74 States have also enacted their own laws
governing the manufacture and sale of non-FDA-approved cannabis
products. These laws vary significantly from state to state. For example,
eleven states and Washington, DC have legalized adult use of cannabis
products, and fifteen states have decriminalized it.75 “Legalization”
refers to removing legal prohibitions against the use of cannabis so that
it is available to the general adult population for purchase and use at
will, similar to the regulation of tobacco and alcohol products.76 In these
states, the laws still contain certain limitations, however, such as
possession limits.77 “Decriminalization” means that cannabis would
remain illegal, but the individual possessing less than a certain amount
of cannabis would not be prosecuted.78 The individual may receive no

69

21 U.S.C. § 321(ff).
21 U.S.C. § 331 (ll)(3)(C).
71 21 U.S.C. § 331.
72 Statement from FDA Commissioner Gottlieb, supra note 67.
73 Statement from FDA Commissioner Gottlieb, supra note 67.
74 Taylor Miller Thomas & Beatrice Jin, The Dis‐United States of Cannabis, POLITICO
(Oct. 1, 2019), https://www.politico.com/interactives/2019/where-is-cannabis-legalillegal-by-state/.
75 Id.
76 Dragan M. Svrakic, et. al, Legalization, Decriminalization & Medicinal Use of
Cannabis: A Scientific and Public Health Perspective, 109:2 MO. MED. 90 (Mar./Apr. 2012).
77 See, e.g., AK. CODE ANN. § 17.38.020; CAL. HEALTH & SAFETY CODE § 11357; COLO. CONST.
ART. XVIII § 16(3).
78 Svrakic, supra note 76.
70

WORTHY (DO NOT DELETE)

2021]

4/27/2021 11:16 PM

DAZED AND CONFUSED

389

penalty at all, civil fines, or may be required to obtain drug education or
treatment.79
Some states permit the use of non-FDA-approved cannabis
products for “medical” purposes. For example, the Maine Medical Use
of Marijuana Act authorizes qualifying patients to obtain or receive
cannabis for a medical use.80 Under this law, a qualified patient is
defined as a “person who has been a resident of the State for at least 30
days and who possesses a valid written certification regarding medical
use of marijuana[.]”81 A medical provider provides the written
certificate for medical use of cannabis, establishing the provider’s
professional opinion that the patient is likely to receive therapeutic or
palliative benefit from cannabis.82
Other states permit limited use of such cannabis products if they
have low levels of THC or if they contain CBD.83 For example, Iowa’s
Medical Cannabidiol Act of 2014 allows consumers to possess or use
FDA-approved CBD products or CBD products containing no more than
three percent THC and “that is delivered in a form recommended by the
medical cannabidiol board, approved by the board of medicine, and
adopted by the [Department of Public Health]” provided that they
receive certification from a health care provider of medical necessity of
such products.84 In other states, such as Idaho, all forms and uses of
cannabis, except for any drugs approved by the FDA, are illegal.85

III.

Analysis

In some states, courts have interpreted state medical marijuana
laws as requiring employers to reimburse employees for non-FDAapproved cannabis products as a workers’ compensation benefit,86 and
other states may soon pass legislation requiring health plans to provide
79

Svrakic, supra note 76.
22 ME. REV. STAT. TIT. 22 § 2423-A (2020).
81 22 ME. REV. STAT. TIT. 22 § 2422(9) (2020).
82 22 ME. REV. STAT. TIT. 22 § 2423-B (2020).
83 State Medical Marijuana Laws, supra note 1.
84 IOWA CODE ANN. §§ 124E.2(6) (2020). “In a prosecution for the unlawful possession
of marijuana . . . for the possession of medical cannabidiol, . . . it is an affirmative and
complete defense to the prosecution that the patient has been diagnosed with a
debilitating medical condition, used or possessed medical cannabidiol pursuant to a
certification by a health care practitioner . . ., and, for a patient eighteen years of age or
older, is in possession of a valid medical cannabidiol registration card[.]” Id. at §
124E.12(4)(a).
85 Thomas & Jin, supra note 74.
86 See Hager v. M&K Const., 225 A.3d 137, 140-41 (N.J. Super. Ct. App. Div. 2020).
80
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coverage for medical use of non-FDA-approved cannabis products. But,
state laws mandating coverage of non-FDA-approved cannabis products
are in direct conflict with and preempted by certain federal laws.
Additionally, such laws open employers up for both criminal and tort
liability.
A. PROPOSED LEGISLATION
In recent years, lawmakers in several states have introduced
legislation to mandate that insurance cover non-FDA-approved
cannabis products as a health benefit.87 These laws would require
health plans to provide payment for such products if used by insured
individuals or employers to reimburse for those products as a workers’
compensation benefit through their workers’ compensation insurance
carrier.88 In January 2020, the New Jersey Assembly introduced A1708,
which requires workers’ compensation and health insurance coverage
for medical use of marijuana.89 In January 2020, Hawaii introduced SB
2586, which requires state-regulated health plans, health maintenance
organizations, and workers’ compensation programs to reimburse
qualifying patients up to a certain monthly and annual dollar amount for
“medical cannabis or manufactured cannabis products.”90 A “qualifying
87

In addition to the bills described in this section, Maine introduced LD942 and
Wisconsin introduced SB377 in 2019, both of which would have required certain health
plans to cover marijuana for medical use. But, both bills died. See, e.g., H.P., 697, 129th
Leg., 1st Sess. (Me. 2019); WI SB 377, 2019-20 Reg. Sess. (Wis.2019).
88 See A. 1708, 219th Leg. (N.J. 2020); S.B. 2054, 2019-20 Reg. Sess. (N.Y. 2020); H.
3875, 191 Gen. Ct. Leg. (Ma. 2019); H.P., 697, 129th Leg., 1st Sess. (Me. 2019); WI S.B.
377, 2019-20 Reg. Session (Wis. 2019).
89 A. 1708, 219th Leg. (N.J. 2020). This bill amends Section 16 of P.L. 2009, which
adopts the definition of marijuana from the New Jersey Controlled Dangerous
Substances Act. “Marijuana” is defined as “all parts of the plant genus Cannabis, whether
growing or not; the seeds thereof; and every compound, manufacture, salt, derivative,
mixture, or preparation of the plant or its seeds, except those containing resin extracted
from the plant; but shall not include the mature stalks of the plant, fiber produced from
the stalks, oil or cake made from the seeds of the plant, any other compound,
manufacture, salt, derivative, mixture, or preparation of such mature stalks, fiber, oil, or
cake, or the sterilized seed of the plant which is incapable of germination.” The
definition excludes “industrial hemp cultivated pursuant to the New Jersey Industrial
Hemp Pilot Program.” Id.; N.J. STAT. ANN. §§ 24:21-2.
90 S.B. 2586 , 30th Leg. S.D. 1 (Haw. 2020). Pursuant to this bill, “medical cannabis”
has the same meaning as “marijuana” and “marijuana concentrate.” Id.; HAW. REV. STAT.
329-121. “Marijuana” is defined as “all parts of the plant (genus) Cannabis whether
growing or not; the seeds thereof, the resin extracted from any part of the plant; and
every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its
seeds, or resin. It does not include the mature stalks of the plant, fiber produced from
the stalks, oil, or cake made from the seeds of the plant, any other compound,
manufacture, salt, derivative, mixture, or preparation of the mature stalks (except the
resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of the plant which is
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patient” is defined as “a person who has been diagnosed by a physician
or advanced practice registered nurse as having a debilitating medical
condition.”91 In January 2019, New York introduced SB 2054, which
requires that certain state-regulated health plans (e.g., exchange plans,
Medicaid, and the Children’s Health Insurance Program (CHIP) and
workers’ compensation) cover marijuana.92
Massachusetts also
introduced a bill that would require state employee health plans,
Medicaid managed care organizations, and other state-regulated plans
to cover “medical use marijuana.”93 All of these bills would mandate
coverage of non-FDA-approved cannabis products.
B. HEALTH COVERAGE & BENEFITS
1. Small Business Group Health Plans
Under the Patient Protection and Affordable Care Act (ACA), states
have regulatory authority over some employer health plans, such as
group plans offered to employers through the Small Business Health
Options Program (SHOP).94
SHOP plans are likely prohibited from covering non-FDA-approved
cannabis products. The ACA contains requirements for exchange plans’
formulary drug lists (i.e., the list of drugs that a particular health plan
has decided to cover).95 For example, the ACA requires pharmacy and
therapeutic committees to base their decisions to include a medication
incapable of germination.” Id. at § 329-1. “Marijuana concentrate” means hashish,
tetrahydrocannabinol, or any alkaloid, salt, derivative, preparation, compound, or
mixture, whether natural or synthesized, of tetrahydrocannabinol. HAW. REV. STAT. §
712-1240 (2020).
91 HAW. REV. STAT. § 329-121 (2020).
92 S.B. 2054, 2019-20 Reg. Sess. (N.Y. 2020). New York Public Health Law defines
“marijuana” as “all parts of the plant of the genus Cannabis, whether growing or not; the
seeds thereof; the resin extracted from any part of the plant; and every compound,
manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin. It
does not include the mature stalks of the plant, fiber produced from the stalks, oil or
cake made from the seeds of the plant, any other compound, manufacture, salt,
derivative, mixture, or preparation of the mature stalks (except the resin extracted
therefrom), fiber, oil, or cake, or the sterilized seed of the plant which is incapable of
germination,” and also includes tetrahydrocannabinols or a chemical derivative of
tetrahydrocannabinol. N.Y. PUB. HEALTH LAW §§ 3302, 3397-b.
93 H. 3875, 191 Gen. Ct. Leg. (Ma. 2019). “Medical use marijuana” is defined as
marijuana that is cultivated, processed, transferred, tested, or sold in compliance with
Massachusetts’s Act to Ensure Safe Access to Marijuana. 935 CMR. § 501.002.
94 42 U.S.C. § 300gg-22(a)(1); 45 C.F.R. § 150.101(b)(2); Blueprint for Approval of
State‐Based Health Insurance Exchanges: Coverage Years Beginning On or After 2019,
CMS,https://www.cms.gov/CCIIO/Resources/Fact-Sheets-andFAQs/Downloads/CMS-Blueprint-Application.pdf (last visited Mar. 24, 2021).
95 45 C.F.R. § 156.122.
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on an exchange plan’s formulary on the “strength of scientific evidence
and standards of practice,” and “the therapeutic advantages of drug in
terms of safety and efficacy.” 96 Non-FDA-approved cannabis products
are Schedule I substances, meaning they lack scientific evidence
establishing their therapeutic value.97 Additionally, given that such
substances have not received FDA approval, their safety and efficacy has
not been demonstrated and cannot be assured. Thus, an exchange plan,
including small business plans offered through the SHOP, would likely
violate the ACA if such substances were included on the plan’s
formulary. Moreover, the ACA contains preemption language, which
notes that states are allowed to adopt and enforce laws that provide
greater consumer protections, but not weaker protections.98 A state law
requiring exchange plans to cover non-FDA-approved cannabis
products would, therefore, likely be preempted by the ACA because it
would weaken consumer protections in the federal law aimed at
ensuring consumers receive safe and effective medications.
2. ERISA
The Employee Retirement Income Security Act of 1974 (ERISA) is
a federal law that establishes minimum standards for employersponsored health plans in the private industry (other than churches).99
ERISA requires plans to: (1) provide participants with plan information;
(2) imposes fiduciary duties upon those who manage and control the
health plan; (3) requires the plan to implement a grievance and appeals
process for participants to access their plan benefits; and (4) provides
participants with the right of action to sue for benefits and breaches of
a fiduciary duty.100 ERISA states that a plan shall “specify the basis on
which payments are made to and from the plan[]” and that the fiduciary
shall administer the plan “in accordance with the documents and
instruments governing the plan[.]”101

96

45 C.F.R. § 156.122(a)(3)(iii)(B-C).
21 U.S.C. § 812(b)(1).
98 42 U.S.C. § 1804(d) (“Nothing in this title shall be construed to preempt any State
law that does not prevent the application of the provisions of this title.”).
99 29 U.S.C. § 1001; ERISA, U.S. DOJ, https://www.dol.gov/general/topic/healthplans/erisa (last visited Feb.. 26, 2021).
100 ERISA, U.S. DOJ, https://www.dol.gov/general/topic/health-plans/erisa (last
visited Feb. 26, 2021).
101 29 U.S.C. §§ 1l02(b)(4), 1l04(a)(1)(D); Egelhoff v. Egelhoff, 532 U.S. 141, 148
(2001) (quoting Fort Halifax Packing Co. v. Coyne, 482 U.S. 1, 9 (1987)).
97
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ERISA preempts all state laws as they “relate to” employersponsored health plans.102 Based on Supreme Court precedent, ERISA’s
preemption clause should be interpreted broadly to allow for national
uniformity of rules that apply to employee benefit programs.103 In
particular, ERISA preempts state laws that: (1) refer specifically to
ERISA plans (i.e., all private employer-sponsored health plans), (2)
mandate employee benefit structures or their administration, (3) offer
different enforcement mechanisms, or (4) constrain employers or plan
fiduciaries to certain choices or prevent uniform administrative
practice.104 As such, unless a provision of ERISA explicitly provides
states with the authority to regulate a particular aspect of an employersponsored plan,105 ERISA preempts state laws that either directly
regulate employer-sponsored plans (e.g., requiring a plan to offer all
employees health insurance) or that indirectly impact the plans (e.g.,
regulating a plan’s formulary).106 Additionally, the Supreme Court has
held that “if an individual, at some point in time, could have brought his
claim under ERISA [to recover benefits due to him, enforce his rights, or
clarify his rights under the terms of the plan], and where there is no
other independent legal duty that is implicated by a defendant’s actions,
then the individual’s cause of action is completely preempted by
ERISA[.]”107
ERISA’s “savings clause” creates an important exception from
preemption, thereby allowing states to regulate “the business of
insurance.”108 The savings clause permits states to “regulate traditional
insurance carriers conducting traditional insurance business.”109 In
other words, it allows states to regulate the terms and conditions of
health insurance (e.g., the benefits in a health plan or the rules under
which the health insurance market must operate). But, the Supreme
102

29 U.S.C. § 1144(a) (stating “the provisions of [ERISA] shall supersede any and all
State laws insofar as they may now or hereafter related to any employee benefit
plan[.]”).
103 Shaw v. Delta Air Lines, 463 U.S. 85, 98 (1983); Metro. Life Ins. Co. v. Mass., 471
U.S. 724, 732 (1985); Alessi v. Raybestos-Manhattan, Inc. 451 U.S. 504, 524 (1981).
104 Egelhoff, 532 U.S. at 148; NY State Conf. of Blue Cross & Blue Shield Plans v.
Travelers Ins. Co., 514 U.S. 645, 658 (1995); Ingersoll-Rand Co. v. McClendon, 498 U.S.
133, 142 (1990); Fort Halifax Packing Co. v. Coyne, 482 U.S. 1, 14 (1987).
105 See, e.g., 42 U.S.C. § 300gg-22(a)(1).
106 ERISA Preemption Primer, THE AUTISM CMTY. IN ACTION, http://tacanow.org/wpcontent/uploads/2011/03/erisa-preemption-primer.pdf (last visited Feb. 26, 2021).
107 Aetna Health Inc. v. Davila, 542 U.S. 200, 210 (2004); see also Conn. State Dental
Ass’n v. Anthem Health Plans, Inc., 591 F.3d 1337, 1345 (11th Cir. 2009) (“The Davila test
thus requires two inquiries: (1) whether the plaintiff could have brought its claim under
§ 502(a); and (2) whether no other legal duty supports the plaintiff’s claim.”).
108 29 U.S.C. § 1144(b)(2)(A).
109 ERISA Preemption Primer, supra note 106.
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Court has ruled that ERISA would preempt state law if the state law
“govern[ed] . . . a central matter of plan administration . . . [or]
interfere[d] with nationally uniform plan administration.”110
The savings clause is subject to an exception known as ERISA’s
“deemer clause.” The deemer clause provides that employer-sponsored
self-insured plans (i.e., plans for which the employer provides all of the
funding and coverage without the assistance of an insurance company)
are not deemed to be insurance and thus not subject to state
regulation.111 The deemer clause does not, however, apply to employersponsored fully-insured plans (i.e., plans for which an insurance
company provides funding).112 As such, while both self-insured and
fully-funded plans are both subject to ERISA, only fully funded plans
may be subject to state regulation.
ERISA would likely prohibit a health plan from providing coverage
of non-FDA-approved cannabis products. ERISA imposes a fiduciary
duty on plan administrators to comply with all federal laws.113 For
example, in Durand v. Hanover Insurance Group,114 a plan administrator
brought suit against the sponsor of an employee pension plan for using
a methodology to calculate lump-sum distributions that did not comply
with the law.115 The Sixth Circuit held that ERISA requires that the plan
administrator act “in accordance with the documents and instruments
governing the plan insofar as such documents and instruments are
consistent with [ERISA].”116 The court also noted that the plan
administrator’s authority to “disregard unlawful plan provisions” was
“derived from [her] own duty to comply with the law.”117 As previously
discussed, all non-FDA-approved cannabis products are illicit under the
CSA and FDCA.118 ERISA would therefore prohibit plan administrators
from offering payment for or coverage of such products because, in
doing so, plan administrators would be breaching their fiduciary duty to
comply with federal laws.
ERISA also would likely preempt any state law mandating that nonFDA-approved cannabis products be a covered benefit for both selffunded plans and fully insured plans. Pursuant to the deemer clause,
110

Egelhoff v. Egelhoff, 532 U.S. 141, 148 (2001).
29 U.S.C. § 1144(b)(2)(B).
112 Metro. Life Ins. Co. v. Mass., 471 U.S. 724, 732 (1985).
113 See Durand v. Hanover Ins. Grp., Inc., 560 F.3d 436, 442 (6th Cir. 2009).
114 Id. at 436.
115 Id. at 437.
116 Durand, 560 F.3d at 442.
117 Id.
118 21 U.S.C. § 812 Schedule 1 (c)(17) (2018); 21 C.F.R. §§ 1308.11(d)(23), (58)
(2020); 21 U.S.C. § 355(a) (2021); FDA Regulation of CBD, supra note 7.
111
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states may not regulate self-funded employer plans. Thus, any state law
mandating coverage of non-FDA-approved cannabis products would
automatically be invalid as it pertains to self-funded plans. Additionally,
such state laws would likely interfere with the nationally uniform plan
administration of fully insured plans.119 State laws legalizing the use of
cannabis vary from state-to-state, and at this point, only a handful of
states have introduced legislation that would mandate health plans to
cover non-FDA-approved cannabis products as a health benefit. Plan
administrators would have to create varying formularies from state-tostate wherein claims for cannabis coverage or reimbursement would be
approved in some states but not others. As such, laws mandating
coverage would interfere with plan administrators’ ability to administer
uniform plans nationally.
3. Workers’ Compensation
Workers’ compensation programs provide benefits to workers
who are injured while working, or whose health conditions or
disabilities were caused or worsened by workplace conditions.120
Benefits are offered without regard to fault and are often the exclusive
remedy offered for workplace injuries and illnesses.121 Workers’
compensation is usually provided through a network of state
programs.122 Employers purchase insurance to provide for workers’
compensation benefits.123 Federal workers’ compensation laws cover
federal civilian employees and their dependents, persons engaged in
maritime employment, seamen, coal miners who develop black lung or
pneumoconiosis, veterans, and railroad workers.124 State workers’
compensation statutes govern most, if not all, other workers.125 Further,
state workers’ compensation laws and the protections provided vary on
a state-by-state basis..126 Workers’ compensation typically covers the
119

Gobeille v. Liberty Mut. Ins. Co., 136 S. Ct. 936, 943 (2016).
CONG. RESEARCH SERV., R44580, WORKERS’ COMPENSATION: OVERVIEW AND ISSUES 1, 13
(2020), https://fas.org/sgp/crs/misc/R44580.pdf.
121 Id. at 1.
122 Id.
123 Id.
124 See Federal Employees’ Compensation Act, 5 U.S.C. §§ 8101-8193 (2016);
Longshore and Harbor Workers’ Compensation Act, 33 U.S.C. §§ 901-950 (2020) ;
Federal Coal Mine Health and Safety Act of 1969, 30 U.S.C. §§ 901-945 (2020); Federal
Employers’ Liability Act, 45 U.S.C. §§ 51-60 (2020); Veterans’ Benefits Act, 38 U.S.C. §
1151 (2020).
125 CONG. RESEARCH SERV., supra note 120, at 1 (“The federal government has only a
limited role in the provision of workers’ compensation because most workers are
covered by state laws.”).
126 See CONG. RESEARCH SERV., supra note 120, at 5-6.
120
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cost of clinical visits, laboratory tests, exams, and medications that are
prescribed to treat an injured or ill employee.127
Coverage of medical marijuana, in particular, differs from state to
state, with courts weighing in on whether reimbursement can be
compelled, given that non-FDA-approved cannabis products are illegal
under the CSA and FDCA.128 For example, medical marijuana laws
exempt certain entities, such as health insurers, from reimbursement
mandates.129 Colorado law provides that “[n]o governmental, private,
or any other health insurance provider shall be required to be liable for
any claim for reimbursement for the medical use of marijuana.”130
These exemptions could also include workers’ compensation plans.
Additionally, Arizona law explicitly states that nothing in its marijuana
laws mandates that “a government medical assistance program, a
private health insurer or a workers compensation carrier or selfinsured employer providing workers compensation benefits to
reimburse a person for costs associated with the medical use of
marijuana.”131 Ohio’s Bureau of Workers’ Compensation goes one step
further and states that it will only cover medications that are FDA
approved, dispensed from a pharmacy, and on a pharmaceutical
formulary.132

127 See, e.g., CAL. LAB. CODE § 4600(a) (2021); Medical & Pharmacy Benefits, NY STATE
INS. FUND, https://ww3.nysif.com/Home/Claimant/WCClaimant/ProviderNetworks
(last visited Feb. 28, 2021); Florida Workers’ Compensation Health Care Provider
Reimbursement
Manual,
45-46
(2016),
https://www.myfloridacfo.com/Division/WC/PublicationsFormsManualsReports/Ma
nuals/Final%20Draft%2069L7.020%20Post%20Hearing%202016HCPRM%2011_30_2016.pdf.
128 See, e.g., Bourgoin v. Twin Rivers Paper Co., 187 A.3d 10, 17 (Me. 2018) (finding
that employers were not required to cover medical marijuana under workers’
compensation); Appeal of Panaggio, 205 A.3d 1099, 1103 (N.H. 2019) (finding that the
insurer was required to cover medical marijuana); Vialpando v. Ben’s Auto. Servs., 331
P.3d 975, 980 (N.M. Ct. App. 2014) (finding that the employer was required to cover
medical marijuana).
129 James Lynch & Lucian McMahon, Haze of Confusion: How Employers and Insurers
Are Affected by a Patchwork of State Marijuana Laws, INS. INFO. INST., 13 (June 2019),
https://www.iii.org/sites/default/files/docs/pdf/marijuanaandemploy_wp_062019.p
df.
130 COLO. CONST. art. XVIII, § 14, (10)(a) (2020); Lynch & McMahon, supra note 129, at
13.
131 ARIZ. REV. STAT. ANN. § 36-2814 (2020); Lynch & McMahon, supra note 129, at 13.
132 Lynch & McMahon, supra note 129; Medical Marijuana and Its Impact on BWC,
OHIO
BUREAU
OF
WORKERS’
COMPENSATION,
1
(Aug.
2018),
https://www.bwc.ohio.gov/downloads/blankpdf/MedMarijuanaImpact.pdf.
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Other states permit coverage of cannabis products. For example,
in Petrini v. Marcus Dairy, Inc.,133 Connecticut’s Workers Compensation
Commission found that medical marijuana is a “reasonable and
necessary medical treatment” that is reimbursable.134 Additionally, in
2015, the Minnesota Department of Labor and Industry promulgated a
rule that excluded “medical cannabis” from its definition of illegal
substance so that it could be reimbursed as a medical treatment.135 But,
laws that would mandate coverage would likely be preempted by
federal law, as discussed below.
C. FEDERAL PREEMPTION AND THE CSA
State laws mandating that health plans or workers’ compensation
plans cover non-FDA-approved cannabis products will likely be
preempted by federal laws, such as the CSA, to the extent that such state
laws conflict with the federal law. The Supremacy Clause of the U.S.
Constitution “unambiguously provides that if there is any conflict
between federal and state law, federal law shall prevail.”136 Federal law
can preempt state law in three ways: (1) “express preemption, where
Congress expressly states that the federal law preempts the state law;”
(2) “field preemption where Congress explicitly or implicitly leaves ‘no
room’ for state law, or where federal law is ‘so dominant’ that it ‘will be
assumed to preclude enforcement’ of state law”; and (3) “by conflict
preemption, where the state law ‘actually conflicts with the federal
law.’”137 Conflict preemption occurs if “compliance with both federal
and state [law] is a physical impossibility” because federal and state law
“irreconcilabl[y] conflict” or if “state law stands as an obstacle to the
accomplishment and execution of the fully purposes and objectives of
Congress.”138
The CSA contains specific conflict preemption language. It states:
No provision of this title shall be construed as indicating an
intent on the part of the Congress to occupy the field in which
that provision operates, including criminal penalties, to the
133 Petrini v. Marcus Dairy, Inc., 2016 WL 6659149 (Conn. Work. Comp. May 12,
2016).
134 Id. at ¶ H.
135 MINN. R. § 5221.6040(7a); Lynch & McMahon, supra note 129.
136 Gonzales v. Raich, 545 U.S. 1, 29 (2005); see U.S. CONST. art. VI, cl. 2 (“This
Constitution, and the Laws of the United States . . . shall be the supreme Law of the
Land.”).
137 Bourgoin v. Twin Rivers Paper Co., 187 A.3d 10, 14 (Me. 2018).
138 Id.
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exclusion of any State law on the same subject matter which
would otherwise be within the authority of the State, unless
there is a positive conflict between that provision of this title
and that State law so that the two cannot consistently stand
together.139
In short, the CSA preempts any state law if (1) a conflict exists
between the CSA and the state law; and (2) compliance with the
requirements of both is impossible.140 In practice, the CSA likely would
not preempt state laws that simply allow for (but do not mandate) the
distribution and possession of marijuana because such laws do not
require an entity to violate a federal law. But, the CSA would preempt a
state law mandating that an entity violates the CSA because the state law
and the CSA would not be able to “consistently stand together,” as
established in Bourgoin v. Twin Rivers.141
1. Case Law Supporting Preemption
In Bourgoin, the Maine Supreme Court held that covering the cost
of injured workers’ marijuana qualified as aiding and abetting unlawful
possession and use of marijuana.142 In that case, the plaintiff sustained
a work-related injury and was initially prescribed opioids.143 The
opioids resulted in severe adverse side effects.144 The plaintiff’s
physician then issued him a certification to use medical marijuana for
chronic back pain.145 The plaintiff successfully petitioned the workers’
compensation board for an order requiring his former employer, the
defendant, to reimburse him for medical marijuana.146 The court was
called upon to determine the relationship between the federal CSA and
the Maine Medical Use of Marijuana Act (MMUMA).147 The court
concluded that, where an employer is subject to an order that would
require it to subsidize an employee’s acquisition of medical marijuana,
there is a positive conflict between federal and state law, and as a result,
the CSA preempts the MMUMA.148 The court noted that marijuana is a
Schedule I drug, and therefore, it is illegal to knowingly or intentionally
139
140
141
142
143
144
145
146
147
148

Id. (citing 21 U.S.C. 903).
Id. at 15.
Id. at 20.
Id.
Bourgoin, 187 A.3d at 13.
Id.
Id.
Id.
Id.
Id.
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“manufacture, distribute, or dispense, or possess with the intent to
manufacture, distribute, or dispense” marijuana.149 The MMUMA allows
a “qualifying patient” to possess a limited amount of marijuana for
medical use.150 Under the MMUMA, a patient is “qualified” if he or she
receives a written certification from a professional that he or she “is
likely to receive therapeutic benefit” from the medical marijuana and
the medical marijuana used “to treat or alleviate the patient’s
debilitating medical condition.”151 The CSA and MMUMA conflict
because under the CSA marijuana has no legitimate medical purposes,
unlike under the MMUMA, which states that it does.152 As such, the court
found that it would be impossible to comply with both the CSA and the
state order to cover medical marijuana as a workers’ compensation
benefit because complying with the order requires aiding and abetting
the illegal possession of marijuana; therefore, observing the CSA
requires violating the MMUMA.153 The court further noted that MMUMA
does not create a “state right to commit a federal crime” and that “a
person’s right to use medical marijuana cannot be converted into a
sword that would require another party, such as [the defendant], to
engage in conduct that would violate the CSA.”154
In discussing the employer’s risk of criminal liability, the court
stated that a federal prosecution can be initiated against a “principal,”
which is defined as any individual who, among other things, aids or
abets a crime.155 A party can be liable for aiding and abetting a crime if
it: (1) took “an affirmative act in furtherance of that offense”, and (2)
acted “with the intent of facilitating the offense’s commission.”156
Ultimately, the court found that marijuana is a Schedule I substance
under the CSA for which it is illegal to “manufacture, distribute, or
dispense, or possess.”157 Thus, if the defendant were to comply with the
administrative order and subsidize the plaintiff’s use of medical
marijuana, the defendant would be engaging in conduct that meets the
elements of criminal aiding and abetting despite state law allowing
medical marijuana use.158 The court stated “[a]s invoked against [the
149

Bourgoin, 187 A.3d at 16.
Id. at 18; 22 M.R.S. §§ 2422(9), 2423-A(1) (authorizing the possession of
marijuana).
151 Bourgoin, 187 A.3d at 18.
152 See id. at 18-19.
153 Id. at 19.
154 Id. at 19-20.
155 Id. at 17 (citing 18 U.S.C. 2(a)).
156 Id. (citing Rosemond v. United States, 134 S. Ct. 1240, 1245 (2014)).
157 Bourgoin, 187 A.3d at 16 (quoting 21 U.S.C.S. § 841(a)(1)).
158 Id. at 17.
150
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defendant], the MMUMA requires what federal law forbids, and the
authority ostensibly provided by the Maine law is ‘without effect.’”159
The court ultimately held that employers are not required to reimburse
employees for the cost of medical marijuana through workers’
compensation programs.160
Likewise, in In re Daniel Wright,161 the Massachusetts Supreme
Judicial Court was asked to determine whether an insurance company
can be required to reimburse an employee for medical marijuana
expenses.162 The claimant sought reimbursement for medical marijuana
to treat chronic pain resulting from a work-related injury.163 The court
ruled that marijuana’s status as a federally illicit substance preempted
the state from ordering a workers’ compensation insurer to cover
medical marijuana expenses.164 Massachusetts law expressly states that
“[n]othing in the law requires any health insurer, or any government
agency or authority, to reimburse any person for the expenses of the
medical use of marijuana.”165 The court stated “[i]f insurers were
required to make such payments, the size and scope of the legalization
of medical marijuana would be substantially expanded, raising concerns
about federal enforcement and preemption.”166 The court went on to
state that unlike patients and providers covered by Massachusetts’s
medical marijuana laws, insurers would “not be participating in the
patient’s use of a federally proscribed substance voluntarily.”167 The
risk of federal prosecution for aiding and abetting in the possession and
distribution of marijuana would involuntarily be imposed upon
insurers.168 The court noted that insurers are commonly engaged in
interstate commerce, which increases federal regulators’ concerns of
CSA violations, and that “[r]equiring interstate insurers to participate in
the Massachusetts medical marijuana scheme would extend the reach of
the Massachusetts act well beyond the Commonwealth’s borders.”169

159
160
161
162
163
164
165
166
167
168
169

Id. at 22 (quoting Mut. Pharm. Co., Inc. v. Bartlett, 570 U.S. 472, 486-87 (2013)).
Id.
In re Daniel Wright, 486 Mass. 98 (2020).
Id. at 98-99.
Id. at 99.
Id.
Id. (quoiting St. 2012, c. 369, §7 (B)).
Wright’s Case, 486 Mass at 109.
Id.
Id. at *21.
Id.
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2. Improper Findings of No Preemption
There are several cases that stand in direct contrast with Bourgoin
and Wright. The courts’ rationale in each of these cases was flawed,
however. For example, in McNeary v. Freehold Township,170 a New Jersey
workers’ compensation judge (WCJ) ruled that the defendant, a selfinsured township, was required to pay for a worker’s medical
marijuana.171 In that case, the defendant refused to cover the medical
marijuana treatment for the worker who had muscular spasticity,
arguing that marijuana was illegal under the CSA and that the CSA
preempts state law.172 The insurer cited Bourgoin for the basis of its
argument.173 But, the WCJ ruled that the CSA did not preempt the state’s
medical marijuana law.174 He noted that the CSA and the New Jersey
Medical Marijuana Act were both intended to deter the distribution and
use of illicit substances for the purposes of the overall general public
health.175 The WCJ did not personally believe that deterring the use of
marijuana for medical purposes achieves the goal of improving general
public health, however.176 Making his own medical judgement, the WCJ
stated that medical marijuana “is safer,” “less addictive,” and “better for
the treatment of pain” than currently marketed opioid analgesics.177
The WCJ also stated that an insurance carrier could not possess,
distribute, or intend to distribute marijuana in violation of the CSA by
providing coverage of the substance.178
The WCJ in McNeary erred because the ruling stands in direct
conflict with the CSA. As noted in Bourgoin, the CSA contains no
170 Order, McNeary v. Freehold Twp., 2008-8094, *1 (N.J. Workers’ Comp. Div., June
28, 2018).
171 Id.
172 McNeary, 2008-8094 at *4, 10, 12.
173 Id. at *6.
174 Id. at *10.
175 Id.
176 Id. at *11–12 (“I honestly don’t feel in my heart of hearts that this is a conflict. . . .
What else is important to note here is in this, Mr. McNeary’s case, there is a documented
medical need and the concern is that Mr. McNeary is going to become addicted to
opioids, [P]ercocet and others. And, quite frankly, this Court is very aware of the
tremendously, the explosion of these narcotics on the streets in the United States in the
last decade, the tremendous amounts of death and addiction that are associated with
these opioids. If there’s anything criminal here, it’s how these drugs have been force fed
to injured people creating addicts. I believe, and I think the science supports this, is that
medical marijuana is safer, it’s less addictive, it is better for the treatment of pain.”).
177 Id. at *11.
178 McNeary, 2008-8094 at *11 (“Certainly I don’t understand how a carrier, who will
never possess, never distribute, never intend to distribute these products, who will
nearly sign a check into an attorney’s trust account is in any way complicit with the
distribution of illicit narcotics.”).
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exception for medical uses of marijuana.179 Instead, the CSA places
marijuana in Schedule I, which is reserved for substances with “high
potential for abuse” and with “no currently accepted medical use in
treatment in the U.S.”180 Had Congress or the DEA determined that
marijuana contained accepted medical uses, it would have removed it
from Schedule I. As such, any conflict between state law and the CSA
should be resolved in favor of the CSA.181 Moreover, while an insurer is
not directly possessing, distributing, or intending to distribute
marijuana, the WCJ failed to consider whether the insurer could be
considered aiding and abetting such actions. Many courts have held that
defendants can be convicted of aiding and abetting drug transactions
because they “contribute to” or “further” such transactions by providing
the “purchase money” for the illicit substances at issue.182
Like the WCJ in McNeary, the Court of Appeals of the State of New
Mexico in Vialpando v. Ben’s Automotive Services183 upheld an order
requiring an employer to reimburse an employee for medical marijuana
treatment.184 In this case, an employee sustained a low back injury.185
He filed for workers’ compensation to cover medical marijuana after his
health care provider certified that his severe chronic pain was
debilitating.186 The WCJ granted his order pursuant to the state’s
Compassionate Use Act (CUA).187 On appeal, the employer argued that
it would be illegal and unenforceable under federal law to reimburse for
medical marijuana.188 The employer further argued that the CUA did not
require reimbursement for medical marijuana.189 The court held that
the CUA did authorize reimbursement for medical marijuana, noting
that the CUA required employers to provide injured workers with
“reasonable and necessary health care services from a health care
provider.”190 The court agreed with the WCJ’s determination that the
employee’s “participation in a course of cannabis in the New Mexico
[M]edical Cannabis Program would constitute reasonable and necessary
179 Bourgoin v. Twin Rivers Paper Co., 187 A.3d 10, 15 (Me. Sup. Jud. Ct. 2018); see
also Gonzales v. Raich, 545 U.S. 1, 27–28 (2005).
180 21 U.S.C. § 812(b)(1).
181 See Gonzales, 545 U.S. at 29.
182 See, e.g., United States v. Garcia-Benites, 702 F. App’x 818, 822 (11th Cir. 2017);
United States v. Tenorio, 360 F.3d 491, 495 (5th Cir. 2004).
183 Vialpando v. Ben’s Auto. Serv., 331 P.3d 975 (N.M. App. Ct. 2014).
184 Id.at 976.
185 Id.
186 Id. at 977.
187 Id.
188 Id. at 976.
189 Vialpando, 331 P.3d at 976.
190 Id. at 977.
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services,” as established by employee’s medical necessity certification
form from his health care provider.191
The employer argued that the WCJ’s order was illegal because it
was contrary to the CSA.192 The court acknowledged that the CSA
classifies marijuana as a Schedule I controlled substance and that any
conflict between the CSA and the CUA should be resolved in favor of the
CSA.193 The court found, however, that in this case, the employer was
not attempting to challenge the legality of the CUA.194 While the
employer asserted that the order to reimburse the employee’s medical
marijuana “essentially requires” the employer to commit a federal
crime, the court also stated that the employer failed to cite to any federal
statute it would be forced to violate.195 The McNeary court therefore
ruled in favor of the plaintiff based on failure to plead proper arguments,
like the arguments made in Bourgoin and Wright.196
In Lewis v. American General Media,197 New Mexico’s CUA was
challenged.198 In that case, another worker who was certified to receive
treatment with medical marijuana sought and received reimbursement
through workers’ compensation.199 The employer challenged a WCJ’s
finding that there was sufficient evidence to support reimbursement for
the marijuana.200 Among other things, the employer argued that the
CUA conflicted with the CSA.201 While the court acknowledged that the
CSA conflicted with the CUA in that the CSA did not except marijuana use
for medical purposes, it still declined to reverse the WCJ’s order.202 The
court noted that then Deputy Attorney General James M. Cole had issued
a federal memorandum (referred to as the “Cole Memo”) with the U.S.
Department of Justice’s (DOJ) position on marijuana enforcement.203
The Cole Memo affirmed that marijuana is illegal under the CSA but did
not identify enforcement against medical marijuana users as a
priority.204 Instead, the Cole Memo noted that the DOJ “would generally
191
192
193
194
195
196
197
198
199
200
201
202
203
204

Id. at 977-78.
Id. at 979.
Id.
Id. at 979-980.
Vialpando, 331 P.3d at 980.
See id.
Lewis v. Am. Gen. Media, 355 P.3d 850 (N.M. App. Ct. 2015).
Id. at 851.
Id. at 852.
Id.
Id.
Id.
Lewis, 355 P.3d at 857.
Id.
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defer to state and local authorities.”205 While the employer argued that
it would be aiding and abetting in a violation of the CSA, the court ruled
that the employer would likely not face liability based on the DOJ’s
position laid out in the Cole Memo.206
The court in Lewis also erred. While the Cole Memo allowed for
discretionary enforcement of the federal law, a conflict between state
and federal law, nevertheless, still exists. Preemption is based upon the
black letter of the law rather than the likelihood of whether that law will
be enforced.207 The Cole memo did not challenge the existence of the
CSA, but merely instituted an internal policy regarding enforcement.208
As stated in Bourgoin, “[p]rosecuted or not, the fact remains that [the
insurer] would be forced to commit a federal crime if it complied with
the directive of” a state law mandate of medical marijuana coverage; the
“magnitude of the risk of criminal prosecution is immaterial.”209 As
noted in Wright, reliance on an internal federal policy is misplaced
because such policies are transitory.210 For example, the current
Administration revoked the Cole Memo in its entirety.211
In Hager v. M&K Construction,212 the Appellate Division of the
Superior Court of New Jersey also held that a WCJ “can order an
employer to reimburse its employee for the employee’s use of medical
marijuana prescribed for chronic pain following a work-related
accident.”213 Similar to Bourgoin, the employer argued that the New
Jersey Compassionate Use Medical Marijuana Act (MMA) was
preempted by the CSA and that the employer would be aiding and
abetting in a violation of the CSA by reimbursing the employee for his
marijuana use.214 Here, as in McNeary, the court determined that the
205

Id.
Id. at 859.
207 See Bourgoin v. Twin Rivers Paper Co., 187 A.3d 10, 21 (Me. Sup. Jud. Ct. 2018)
(referring to the “Ogden Memo,” a predecessor to the Cole Memo).
208 See id.
209 See id.
210 In re Daniel Wright, SJC-12873 at *12-13 ([“T]he Department of Justice has
reversed its own stance toward the prosecution of medical marijuana cases multiple
times. The Department of Justice issued a series of memoranda during the
administration of President Barack Obama advising Federal prosecutors not to
prioritize the prosecution of individuals engaged in marijuana-related activities
pursuant to a State medical marijuana law. . . . This guidance was later rescinded under
the administration of President Donald Trump.”).
211 Memorandum from the Attorney General on Marijuana Enforcement (Jan. 4,
2018),
available
at
https://www.justice.gov/opa/pressrelease/file/1022196/download.
212 Hager v. M&K Const., 462 N.J. Super. 146 (App. Div. 2020).
213 Id. at 152.
214 Id.
206
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WCJ’s order does not require the employer to possess, manufacture, or
distribute marijuana, and therefore, there is no conflict between the
MMA and the CSA.215 The court further held that the employer lacked
the specific intent required to aid and abet in an offense under federal
law, and that “one cannot aid and abet a completed crime.”216 The court
reasoned that the employer was simply paying for the employee’s
medical expense and not purchasing or distributing marijuana on the
employee’s behalf, and that the employee obtained the drug prior to the
reimbursement.217 The court further held that the employer was not an
active participant in the commission of a crime but rather merely
complying with state law.218
The arguments in Hager are flawed. First, as established, while the
employer is not directly possessing, manufacturing, or distributing
marijuana, it is aiding and abetting in the possession of marijuana if it
reimburses for such products. The court is incorrect in reasoning that
the employer lacks “intent” to aid and abet. As set forth in Rosemond v.
United States,219 “for purposes of aiding and abetting law, a person who
actively participates in a criminal scheme knowing its extent and
character intends that scheme’s commission,” and on that basis, is
criminally liable.220 An employer knowingly violates the CSA by
reimbursing for marijuana because the employer is required to submit
all workers’ compensation claims for processing. Thus, the employer is
not just paying for expenses in a black box; the employer is fully aware
that the employee is seeking to possess marijuana in violation of the
CSA. As such, in reimbursing for the marijuana, the employer is aiding
in the commission of the crime. Moreover, it cannot be a defense to a
federal law that a party complied with a state law; otherwise, the
preemption doctrine would be reversed, and states could completely
disregard federal criminal law. Finally, it is inaccurate to state that an
insurer or employer would not aid and abet by reimbursing the cost of
marijuana after it has been purchased because it is impossible to aid and
abet a completed crime. By offering coverage of marijuana as a workers’
compensation or health benefit, an insurer is making a future promise
to reimburse marijuana costs. Because courts have held that a promise
of future payment is equivalent to payment before the fact, the payment

215
216
217
218
219
220

Id. at 153.
Id. at 166.
Id.
Hager, 462 N.J. Super. at 166.
Rosemond v. United States, 572 U.S. 65 (2014).
Id. at 77.
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itself furthers the crime’s commission.221 The promise of payment for
marijuana expenses, therefore, encourages the crime of marijuana
possession.
Other courts have danced around the issue of federal preemption.
For example, in In re WDF Inc.,222 New York Workers’ Compensation
Board determined that medical marijuana is reimbursable if certain
criteria are met.223 It noted that the state’s Public Health Law (“Medical
Use of Marijuana”) permits marijuana to be “prescribed” to treat several
medical conditions and that the state law is not preempted merely
because the law had not yet been invalidated by the Second Circuit or
the New York Court of Appeals under federal preemption doctrine.224
Likewise, in Appeal of Andrew Panaggio,225 the New Hampshire Supreme
Court determined that the lower court erred when it held that the state’s
workers’ compensation law prohibited an insurer from reimbursing for
medical marijuana because marijuana treatment was “reasonable,
medically necessary and causally related to [the] work injury.”226 The
court remanded the case so the lower court could determine whether
reimbursement would violate federal laws.227
One could argue that state laws requiring coverage of marijuana
products, including cannabis-derived CBD containing more than 0.3
percent THC, similar to the ones proposed in New Jersey, New York, and
Hawaii, would violate the CSA for the reasons discussed in Bourgoin and
Wright. The CSA would preempt those laws because they require
insurers and employers to take an action in violation of the CSA. The
state law and the CSA “cannot consistently stand together.”228
Moreover, such laws would require insurers or employers to commit the
federal crime of aiding and abetting marijuana possession.
D. FDCA
State laws mandating the coverage of non-FDA-approved cannabis
products undermine the purpose and intent of the FDCA, thereby posing
a risk to public health and safety.

221 See, e.g., United States. v. Camargo-Vergara, 57 F.3d 993, 1001 (11th Cir. 1995);
United States. v. Mitchell, 944 F.3d 116, 120 (3d Cir. 2019).
222 2017 NY Wrk Comp G1403803 (N.Y. Workers’ Comp. Bd. June 6, 2017).
223 Id.
224 Id.
225 In Re Panaggio, 205 A.3d 1099 (N.H. Sup. Ct. 2019).
226 Id. at 1103.
227 Id. at 1105. A subsequent opinion from the remand is not available at the time of
writing.
228 Bourgoin, 187 A.3d at 20 (citing 21 U.S.C. 903)
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1. Unapproved New Drugs and Misbranded Drugs
State laws mandating the coverage of non-FDA-approved cannabis
products promote the violation of the FDCA. As explained above, when
intended for use as a “drug” (i.e., to diagnose, cure, mitigate, treat, or
prevent disease),229 cannabis products must obtain FDA approval
before they can be marketed or distributed in interstate commerce.230
To date, the FDA has approved one cannabis-derived product and three
synthetic cannabis-related drug products.231 To the extent that they are
used, or intended for use, to treat a medical condition, all other nonFDA-approved cannabis products are considered unapproved new
drugs and are illegal under the FDCA.232 Unapproved new drugs create
significant risks to patients because the FDA has not reviewed such
substances for safety, effectiveness, or quality.233
In recent years, the FDA has engaged in enforcement actions
against parties that manufacture, distribute, market, or sell non-FDAapproved cannabis products.234 State medical marijuana laws that allow
for the distribution, sale, and possession of non-FDA-approved cannabis
products are in direct conflict with the FDCA because they permit
parties to introduce, or cause to be introduced, non-FDA-approved and
misbranded products into interstate commerce if a health care provider
certifies that a patient has a legitimate medical need for such products.

229

21 U.S.C. § 321 (g)(1)(B).
See 21 U.S.C. § 321(g)(1).
231 Those products are Epidiolex (cannabidiol), Marinol (dronabinol), Syndros
(dronabinol), and Cesamet (nabilone). FDA and Cannabis: Research and Drug Approval
Process,
FDA,
https://www.fda.gov/news-events/public-health-focus/fda-andcannabis-research-and-drug-approval-process (last updated Oct. 1, 2020).
232 What You Need to Know (And What We’re Working to Find Out), supra note 12. The
FDA “permits some unapproved drugs to be marketed if:
The drug is subject to an open drug efficacy study implementation (DESI)
program proceeding,
1) Health care professionals rely on the drug to treat serious medical
conditions when there is no FDA-approved drug to treat the
condition,
2) There is insufficient supply of an FDA-approved drug.
3) The law allows some unapproved prescription drugs to be lawfully
marketed if they meet the criteria of generally recognized as safe and
effective (GRASE) or grandfathered. But, the agency is not aware of
any human prescription drug that is lawfully marketed as
grandfathered.”
Unapproved Drugs, FDA, (Oct. 26, 2020),
https://www.fda.gov/drugs/enforcement-activitiesfda/unapproved-drugs.
233 21 U.S.C. § 393(b)(2); Unapproved Drugs, supra note 232.
234 FDA Warns 15 Companies, supra note 5.
230
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Under the FDCA, the FDA has sole authority over drug approval and
labeling.235 Yet, state medical marijuana laws effectively allow states to
make their own judgments about a drug’s safety and efficacy. Some
states even have a list of medical conditions for which the law is
applicable.236 These laws thereby stand in conflict with the FDCA.237
State law cannot “stand[] as an obstacle to the accomplishment and
execution of the full purposes and objectives of Congress.”238 For
example, in Zogenix, Inc. v. Patrick,239 the United States District Court for
the District of Massachusetts found that the FDCA preempted a state
order banning an FDA-approved drug.240 In that case, the court noted
that while a state’s police powers permit it to regulate the
administration of drugs by the health professionals, the state may not
exercise those powers in a way that is inconsistent with federal law,
including the FDCA’s objective that safe and effective drugs be available
to the public.241
Likewise, in Ouellette v. Mills,242 the U.S. District Court for the
District of Maine held that the FDCA preempted a state law permitting
the importation of foreign drugs that the FDA had not approved.243 The
state had passed a law to allow Maine residents to import prescription
drugs from international mail order pharmacies.244 The court noted,
however, that the FDCA “prohibits the importation or introduction into
interstate commerce of any ‘new drug’ that has not received FDA
approval.”245 Similarly, states that permit distribution and possession
of non-FDA-approved cannabis products directly conflict with the FDCA
by promoting the distribution of products that the FDA has not deemed
to be safe and effective.
State laws mandating coverage of non-FDA-approved cannabis
products further the notion that these products are safe and effective to
235 Mut. Pharm. Co. v. Bartlett, 570 U.S. 472, 486 (2013); see, e.g., Zogenix, Inc. v.
Patrick, 2014 WL 1454696, at *1 (D. Mass. Apr. 15, 2014) (holding state order banning
drugs which FDA had approved was preempted); Ouellette v. Mills, 91 F. Supp. 3d 1, 4
(D. Me. 2015) (holding state law permitting importation of foreign drugs FDA had not
approved was preempted).
236 State Medical Marijuana Laws, supra note 1.
237 Bartlett, 570 U.S. at 486; see, e.g., Zogenix, 2014 WL 1454696 at *1; Ouellette, 91 F.
Supp. 3d at 4.
238 Arizona v. United States, 567 U.S. 387, 399 (2012).
239 Zogenix, Inc. v. Patrick, 2014 WL 1454696, at *1 (D. Mass. Apr. 15, 2014).
240 Id. at *1.
241 Id. at *4.
242 Ouellette v. Mills, 91 F. Supp. 3d 1, 4 (D. Me. 2015).
243 Id.
244 Id.
245 Id. at 5.
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treat medical conditions, despite the lack of approval. The FDA has
stated that more clinical trials are needed to study and assess the safety
and efficacy of cannabis products to treat medical conditions.246 Yet,
state coverage mandates authorize health plans to reimburse patients
who use such products for treatment purposes. In doing so, these
coverage mandates create and promote a market for unapproved and
unlawful drugs. Health care practitioners may direct their patients to
purchase non-FDA-approved cannabis products, knowing that such
products will be covered. These patients may not have otherwise
purchased such products, and instead, may have been prescribed FDAapproved drugs proven to be safe and effective in treating their
conditions. As such, these state mandates would create an incentive for
patients to purchase and use unregulated substances that are
potentially unsafe and ineffective and that are sold by entities who
violate the FDCA.
Additionally, these state laws would incentivize the purchase of
drugs that are often deceptively marketed, given that many
manufacturers of cannabis products have misleadingly advertised their
products with therapeutic claims, stating that such products can treat,
mitigate, or even cure certain health conditions. Making such
misleading claims is a violation of the FDCA.247 Currently, rigorous
scientific data does not exist to establish that these non-FDA-approved
cannabis products are effective in treating the medical conditions that
they claim to treat.248 For example, in April 2020, the FDA issued a
warning letter to Homero Corp. for marketing its CBD products as
dietary supplements in violation of the FDCA.249 The FDCA states that if
a product contains an active ingredient in a drug product that has been
FDA-approved, then it does not meet the definition of dietary
supplement.250 Additionally, Homero made claims that their non-FDAapproved CBD products could be used to diagnose, cure, mitigate, treat,
or prevent a disease.251 In particular, Homero’s website stated that its
CBD products could “alleviat[e] severe withdrawal symptoms
associated with opiate dependency,” and could be used to treat AIDS,
246

FDA Regulation of CBD, supra note 7.
FDA Warns 15 Companies, supra note 5.
248 FDA and Cannabis: Research and Drug Approval Process, supra note 231.
249 Warning Letter: Homero Corp DBA Natures CBD Oil Distribution, FDA (Apr. 20,
2020),https://www.fda.gov/inspections-compliance-enforcement-and-criminalinvestigations/warning-letters/homero-corp-dba-natures-cbd-oil-distribution605222-04202020.
250 Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 321(ff)(3)(B)(i), (ii); Warning
Letter: Homero Corp DBA Natures CBD Oil Distribution, supra note 249.
251 Warning Letter: Homero Corp DBA Natures CBD Oil Distribution, supra note 249.
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Alzheimer’s Disease, autism, cancer, diabetes, heart disease, kidney
disease, Parkinson’s disease, and others.252 Yet, the FDA noted that
Homero’s CBD products were not generally recognized as safe and
effective for the aforementioned uses, and therefore, the products were
considered “new drugs.”253 New drugs may not be legally introduced
into interstate commerce without prior approval from the FDA.254
These deceptive marketing activities provide consumers with a false
sense of security that the products they are taking are safe and beneficial
to their health.
2. General Safety and Efficacy Concerns
The FDA has stated that non-FDA-approved cannabis products
“can have unpredictable and unintended consequences, including
serious safety risks” and that “there has been no FDA review of data
from rigorous clinical trials to support that . . . unapproved products are
safe and efficacious.”255 Recent studies support the FDA’s statements.
Given that non-FDA-approved cannabis products are not required to go
through rigorous safety and efficacy protocols and lack standards for
quality, purity, and dosage, many have been found to be adulterated
with undisclosed substances, including high levels of THC, heavy metals,
toxins, and mold. For example, one study found synthetic, psychoactive
adulterants, such as “spice” / “K2,” and other dangerous illicit
substances in one third of the CBD vape oils that it tested.256 Another
study from 2019 showed that 70 percent of the CBD products tested
were “highly contaminated” with heavy metals, such as lead and arsenic,
herbicides, and pesticides.257 Additionally, an FDA study published in
July 2020 found that 49 percent of tested CBD products had THC levels
above the Limit of Quantification.258 A different study published in 2020

252

Warning Letter: Homero Corp DBA Natures CBD Oil Distribution, supra note 249.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 331(d), 355(a); Warning Letter:
Homero Corp DBA Natures CBD Oil Distribution, supra note 249.
254 21 U.S.C. § 355(a).
255 FDA and Cannabis: Research and Drug Approval Process, supra note 249.
256 Holbrook Mohr, Some CBD Vapes Contain Street Drug Instead of the Real Thing,
AP NEWS (Sept. 16, 2019), https://apnews.com/article/7b452f4af90b4 620ab0ff0eb
2cca62cc.
257 Fletcher, supra note 14.
258 Sampling Study of the Current Cannabidiol Marketplace to Determine the Extent
that Products are Mislabeled or Adulterated, U.S Food and Drug Administration, 6 (2020),
https://aimedalliance.org/wp-content/uploads/2020/07/CBD-MarketplaceSampling_RTC_FY20_Final.pdf.
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showed that 27 percent of the leading CBD brand products contain
dosages that differ from what is indicated on their labels.259
A recent survey highlighting consumer confusion about CBD
products is also concerning. It found that 21 percent of respondents
said they continue to take more of their CBD product of choice until they
“feel something,” 15 percent said they “estimated” their dosages, and 15
percent said they were not sure of how much they took.260 Only half of
respondents said they referred to the product labels on dosage.261 If
these products contain high levels of THC or other harmful adulterants
and consumers are taking more than the recommended dose, they could
experience harmful side effects. For example, the FDA recently stated
that CBD toxicity could result in such adverse events as liver injury,
interactions with other drugs, drowsiness, diarrhea, and changes in
mood.262 Additionally, the United States Army issued a public health
warning in 2018 after approximately sixty people over the course of a
few months presented health issues linked to adulterated CBD products
at medical centers at two bases in North Carolina.263 Symptoms
included headaches, nausea, vomiting, disorientation, agitation, and
seizures.264 A few months later, North Carolina health officials issued
their own warning after approximately thirty people presented in the
emergency departments with hallucinations, loss of consciousness, and
heart irregularities linked to adulterated CBD.265
Similarly, the Nevada Department of Taxation recently issued a
public health and safety advisory because it identified several non-FDAapproved cannabis products (i.e., raw cannabis buds and raw cannabis
in pre-rolled cigarettes) that contained yeast, mold, bacteria, and fungi,
which are particularly dangerous to consumers with suppressed

259 Maria Loreto, Leading CBD Brands Still Have Some Inaccurate Dosages, Even If
Their Numbers Have Improved, CHICAGO TRIBUNE (June 17, 2020),
https://www.chicagotribune.com/marijuana/sns-tft-cbd-inaccurate-dosages20200617-vizdcxchijbqbpf5ofqvbvjtcm-story.html.
260 Hank Schultz, Research Confirming Consumers’ Confusion Points to Yawning Gap in
CBD Market Surveillance, NUTRA (May 21, 2020), https://www.nutraingredientsusa.com/Article/2020/05/21/Research-confirming-consumers-confusion-points-toyawning-gap-in-CBD-market-surveillance.
261 Id.
262 FDA Warns 15 Companies, supra note 5.
263 Mark Hay, Everything We Know About the Health Risks of Vaping CBD, VICE, Aug.
27, 2018, https://tonic.vice.com/en_us/article/zmk55a/everything-we-know-aboutthe-health-risks-of-vaping-cbd; Public Health Alert: Health Effects of Vape Oils Containing
Unknown
Substances,
ARMY
PUB.
HEALTH
CTR.,
Aug.
31,
2020,
https://phc.amedd.army.mil/topics/healthyliving/tfl/Pages/VapeOils.aspx.
264 Hay, supra note 263.
265 Hay, supra note 263.
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immune systems.266 These products had been sold legally at thirty
dispensaries within the state.267 Likewise, a Hawaii Department of
Health whistleblower identified a lack of proper controls over Hawaii’s
marijuana dispensaries.268 The whistleblower, a board-certified
cannabis physician in the state, noted that at least a third of his patients
reported safety concerns with vaping cartridges containing THC oils
purchased from state-regulated shops.269 Tests of the oils showed
dangerously high concentrations of ethanoyl (e.g., ten times the ethanol
allowed in Colorado), which can cause eye, lung, nose, and throat
irritation among other harms.270
E. DRUG-FREE WORKPLACE ACT
Non-FDA-approved cannabis products also pose a risk for
employers because they could result in impairment in the workplace.
According to the National Alliance of Healthcare Purchasers Coalition,
“THC in cannabis has an intoxicating effect that can affect an individual’s
motor skills, reaction time, and coordination at low levels (as little as 2.5
milligrams to 5 milligrams).”271
If an employee is impaired in the workplace, the employer may face
liability, including loss of federal contracts, under the Drug-Free
Workplace Act of 1988 (DFWA).272 Under the DFWA, employers that
have entered into federal contracts, or who have received federal grants,
must make good faith efforts to maintain a drug-free workplace.273 If
they receive more than $25,000, then they must also provide
266 Public Health and Safety Advisory 2020‐05, STATE OF NEV., DEP’T OF TAXATION, Feb.
21, 2020, https://tax.nv.gov/uploadedFiles/tax.nv.gov/ Content/MME/ Public%
20Health%20and%20Safety%20Advisory%20Cannex%202020-05%20(006).pdf;
Jenny Kane, Another Marijuana Health Advisory Issued for Products Sold at 30
Dispensaries in Nevada, RENO GAZETTE JOURNAL, Feb. 24, 2020,
https://www.rgj.com/story/news/marijuana/2020/02/24/nevada-dispensariessold-tainted-marijuana-pot-health-advisory-issued/4857545002/.
267 Id.
268 Allyson Blair, State‐Regulated Marijuana Vape Cartridges Aren’t Safe, Doctor and
Whistleblower
Say,
HAWAII
NEWS
NOW,
June
3,
2020,
https://www.hawaiinewsnow.com/2020/06/03/state-regulated-marijuana-vapecartridges-arent-safe-doctor-whistleblower-say/.
269 Id.
270 Id.
271 Clinical Brief: Medicinal Uses of Cannabis‐Derived Products, NAT’L ALLIANCE OF
HEALTHCARE PURCHASER COALITIONS, https://www.nationalalliancehealth.org/resourcesnew (last visited March 13, 2021).
272 George Fitting, Careless Conflicts: Medical Marijuana Implications for Employer
Liability in the Wake of Vialpando v. Ben’s Automotive Services, 102 IOWA L. REV. 259, 269
(2016).
273 41 U.S.C. §§ 8102–8103.
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certification of such efforts.274 If the employer is unable to make such
good faith efforts, it is considered to be in material breach of its contract;
payments may be suspended, the contract may be terminated, and the
contractor can be suspended or debarred as a government
contractor.275 If the employer makes a false certification regarding its
good faith efforts, it may be subject to federal prosecution.276 “Drug-free
workplace” is defined as “a site of an entity (A) for the performance of
work done in connection with a specific contract or grant . . .; and (B) at
which employees of the entity are prohibited from engaging in the
unlawful manufacture, distribution, dispensation, possession, or use of
a controlled substance.”277
Given that non-FDA-approved cannabis products are illegal under
the CSA, use of such products would be considered unlawful under the
DFWA, triggering certain remediation steps by the employer (e.g.,
encouraging drug counseling, rehabilitation, or use of employee
assistance program, or imposing penalties on the employee for drug
abuse violations).278 If the employer is required to cover such products
through a health plan or workers’ compensation, however, it is unlikely
the employer could certify that it is making a good faith effort to
maintain a drug-free workplace. While employers could require
employees to only use such substances while they are not working, the
substances may still remain in the employees’ systems even when they
are working.279 Consequently, a drug test may not be able to distinguish
between on-site and off-site drug use. Additionally, a recent study
showed that drug testing methodology often cannot distinguish
between CBD and THC even if THC levels within the CBD product are no
more than 0.3 percent – the cutoff concentration for a product to
become illegal marijuana rather than legal hemp.280 Furthermore, in
University of Hawai’i Professional Assembly v. Tomasu281 the Supreme
Court of the State of Hawaii found that to comply with the DFWA
employers must both have a policy against drug use and implement that

274

18 C.F.R. § 1316.7.
18 C.F.R. § 1316.7.
276 18 C.F.R. § 1316.7.
277 41 U.S.C. § 8101(a)(5).
278 41 U.S.C. §§ 8101(a)(1), 8102(a)(1), 8104.
279 Priyamvada Sharma, et. al., Chemistry, Metabolism, and Toxicology of Cannabis:
Clinical Implications, 7(4) IRAN J. PSYCHIATRY 149, 153 (2012) (“The half-life of [THC] for
an infrequent user is 1.3 days and for frequent users 5-13 days.”).
280 Amanda Chicago Lewis, CBD or THC? Common Drug Test Can’t Tell the Difference,
N.Y. TIMES (Oct. 15, 2019), https://www.nytimes.com/2019/10/15/science/cbd-thccannabis-cannabidiol.html.
281 Univ. of Haw. Prof’l Assembly v. Tomasu, 900 P.2d 161 (Haw. 1995).
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policy by engaging in affirmative disciplinary action against an
employee who fails a drug test.282 The DFWA does not contain any
exceptions for employers bound by state law.283
F. OCCUPATIONAL SAFETY AND HEALTH ACT
State laws mandating coverage of non-FDA-approved cannabis
products could also expose employers to liability under the
Occupational Safety and Health Act of 1970 (OSH Act) if employees are
impaired. The OSH Act imposes a general duty on employers to “furnish
to each of his employees employment and a place of employment which
are free from recognized hazards that are causing or are likely to cause
death or serious physical harm to his employees” (“General Duty
Clause”).284 The Occupational Safety and Health Administration (OSHA)
has strongly supported “measures that contribute to a drug-free
environment and reasonable programs of drug testing within a
comprehensive workplace program for certain workplace
environments, such as those involving safety-sensitive duties like
operating machinery.”285
While the OSH Act and its implementing regulations do not
explicitly require a drug-free workplace, OSHA has stated that, in some
situations, OSHA’s General Duty Clause may be applicable “where a
particular hazard is not address by any OSHA standard.”286 OSHA has
stated that the four components of the General Duty Clause are:
(1) the employer failed to keep its workplace free of a
“hazard;” (2) the hazard was “recognized” either by the
cited employer individually or by the employer’s industry
generally; (3) the recognized hazard was causing or was
likely to cause death or serious physical harm; and (4)
there was a feasible means available that would eliminate
or materially reduce the hazard.287

282

Id. at 169–70 (“[M]ere promulgation of a policy that proclaims compliance with a
federal statute will not constitute compliance with that statute . . . . [T]he DFWA
inherently mandates implementation[.]”); Fitting, supra note 272, at 269.
283 Fitting, supra note 272, at 269.
284 29 U.S.C. § 654(a)(1).
285 Letter from John B. Miles, Director of Enforcement Programs, Occupational Health
and Safety Administration to Patrick J. Robinson, Safety Coordinator, Starline
Manufacturing Co., Inc., (May 2, 1998), OSHA ARCHIVE, https://www.osha.gov/lawsregs/standardinterpretations/1998-05-02.
286 29 U.S.C. § 654(a)(1); Letter from John B. Miles to Patrick J. Robinson, supra note
285.
287 Letter from John B. Miles to Patrick J. Robinson, supra note 285.
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The duty only arises if all four elements are present.288 Violations of the
OSH Act may include a civil penalty ranging from $5,000 to $70,000 and
imprisonment.289
If an employer must cover non-FDA-approved cannabis products
and employees are impaired while in the workplace, then the workplace
may not be free of hazard. The risk of impairment from marijuana use
is generally recognized in industries with safety-sensitive positions. For
example, a 2019 survey from the National Safety Council (NSC) showed
that 81 percent of employers were concerned about marijuana having a
negative impact on their workforce.290 As a result, the NCS has stated
that no amount of marijuana or other THC products should be allowed
for employees working in safety-sensitive positions given the impact of
cannabis on the worker’s psychomotor skills and cognitive ability.291
Additionally, serious physical harm or death is foreseeable when an
impaired employee completes safety-sensitive duties, such as operating
heavy machinery or dealing with hazardous chemicals. For example,
according to the National Institute on Drug Abuse, employees who
tested positive for marijuana had 55 percent more industrial accidents
and 85 percent more injuries than those who tested negative for
marijuana use.292 While the adoption of a drug-free workplace policy
would be a feasible means of eliminating or materially reducing the
hazard, state laws mandating coverage of medical marijuana interfere
with employers’ ability to successfully implement such a policy.
G. TORT LIABILITY
Finally, an employer could be liable for the acts of an impaired
employee if such employee injures a third party or causes damage to the
third party’s property while acting within the scope of their
employment.293 The third party could sue under common law tort
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Letter from John B. Miles to Patrick J. Robinson, supra note 285..
29 U.S.C. § 666.
290 NSC to Employers: Allow NO Cannabis Use Among Workers in Safety Sensitive
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22,
2019),
https://www.ishn.com/articles/111721-nsc-to-employers-allow-no-cannabis-useamong-workers-in-safety-sensitive-positions.
291 Id.
292 Marijuana Research Report: How Does Marijuana Use Affect School, Work, and
Social
Life?,
NAT’L
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DRUG
ABUSE
(July
2020),
https://www.drugabuse.gov/publications/research-reports/marijuana/how-doesmarijuana-use-affect-school-work-social-life.
293 See, e.g., Otis Eng’g Corp. v. Clark, 668 S.W.2d 307, 311 (Tex. 1984) (holding that
an employer has a duty to exercise reasonable prudence to prevent an employee from
“causing an unreasonable risk of harm to others” after the employer permitted a visibly
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doctrine of vicarious liability, including respondeat superior.294
Respondeat superior has been used to hold employers liable in
situations in which employees injured or assaulted others as a result of
intoxication or drug use.295 Under the theory of respondeat superior,
employers are vicariously liable for the actions of their employees.296 To
hold an employer liable under respondeat superior, plaintiffs usually
must satisfy the scope-of-employment test.297
The scope-ofemployment test requires that an employee “be acting, at least in part,
with the motivation to be about the employer’s business” and the
employee’s action must be foreseeable.298
For example, in Ira S. Bushey & Sons, Inc. v. United States,299 a
drydock owner sued the United States after a member of the U.S. Coast
Guard returned to his ship under the influence of alcohol and turned the
drydock’s water flow control valves, causing the drydock’s tanks to
flood.300 As a result, the ship listed, slid off its blocks, and fell against the
wall, partially sinking the ship and the drydock.301 The defendant
argued that it should not be held liable for the actions of its employee
because the employee was not acting “within the scope of
employment.”302 The Second Circuit Court of Appeals noted that
vicarious liability is based on foreseeability.303 It stated that the Coast
Guard member’s conduct “was not so ‘unforeseeable’ as to make it
unfair to charge the government with responsibility . . . . The employer
should be held to expect risks . . . which arise ‘out of and in the course
of’ his employment of labor.”304 The court noted that “it was foreseeable
that crew members crossing the drydock may negligently or even
intentionally damage it.”305 Additionally, the court noted that it was
foreseeable that a seaman would “find solace for solitude by copious
intoxicated employee to drive home, resulting in a fatal automobile accident). Fitting,
supra note 272, at 271–72.
294 Laura L. Hirschfield, Legal Drugs? Not Without Legal Reform: The Impact of Drug
Legalization on Employers Under Current Theories of Enterprise Liability, 7 CORNELL J. L &
PUB. POL’Y 757, 760 (1998).
295 Fitting, supra note 272, at 271–72.
296 Fitting, supra note 272, at 271–72.
297 Fitting, supra note 272, at 271.
298 Fitting, supra note 272, at 271-72.
299 Ira S. Bushey & Sons, Inc. v. United States, 398 F.2d 167 (2d Cir. 1968).
300 Id. at 168.
301 Id.
302 Id. at 170.
303 Id. at 172.
304 Bushey & Sons, Inc. v. United States, 398 F.2d 167, 171-72; Hirschfield, supra note
294, at 796.
305 Bushey & Sons, 398 F.2d at 172.
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resort to the bottle while ashore.”306 The court therefore ruled that the
U.S. was vicariously liable for the Coast Guard member’s actions.307
Likewise, under the proposed state laws, an employer may be
required to cover non-FDA-approved cannabis products as part of
workers’ compensation benefits, or an employee may have a health plan
that covers such products. It would be foreseeable that an employee
under the influence of THC while acting within his or her scope of work,
could cause injury or property damage, resulting in vicarious liability
for the employer.
H. OTHER DISINCENTIVES TO COVER MARIJUANA PRODUCTS
Currently, many health plans only cover FDA-approved drugs with
limited exceptions.308 Health plans generally do not cover non-FDAapproved products because they have not undergone the FDA’s rigorous
safety and efficacy process, and as such, there is no way to guarantee
such products’ potency, dosage, or purity. In addition, non-FDAapproved products are not required to comply with good manufacturing
practices.309
Moreover, employers may be hesitant to cover non-FDA-approved
products through workers’ compensation or health plans because doing
so could be seen as condoning the use of such products at work. Yet, if
an employee is under the influence in the workplace, the employee
could face negative repercussions and the employer could be subject to
liability. For example, the U.S. Department of Transportation (DOT) has
a zero-tolerance policy for marijuana use and has announced that state
initiatives have no bearing on the DOT’s regulated drug testing
program.310 The policy states that the DOT “will not verify a drug test as
negative based upon information that a physician recommended that
the employee use ‘medical marijuana’ when states have passed ‘medical
marijuana’ initiatives” because the DOT “want[s] to assure the traveling
306

Id. at 171-72; Hirschfield, supra note 294, at 796.
See Bushey & Sons, 398 F.2d at 172.
308 See, e.g., Commercial Claim Payment Bulletin – Pharmacy Benefit: Non‐FDA
Approved
Products
(Jan.
1,
2021),
INDEPENDENCE
BLUE
CROSS,
https://www.ibx.com/documents/35221/56638/non-fda-approvedmedication.pdf/2b052ab2-2194-3502-f044-f3ecd5082a1f?t=1593556692733; Drugs
Never
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PRIORITY
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https://www.priorityhealth.com/medicare/drug-coverage/covered-drugs/nevercovered (last visited Feb. 28, 2021) (noting that nonprescription drugs and non-FDAapproved products are excluded from coverage).
309 DOT “Recreational Marijuana” Notice, U.S. DEP’T TRANSP. (Feb. 1, 2017),
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310 Id.;
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18,
2020),
https://www.transportation.gov/odapc/cbd-notice.
307

WORTHY (DO NOT DELETE)

418

SETON HALL LEGISLATIVE JOURNAL

4/27/2021 11:16 PM

[Vol. 45:2

public that [the] transportation system is the safest it can possibly
be.”311 Additionally, the DOT issued a policy on hemp-derived CBD
products containing less than 0.3 percent of THC.312 The DOT notes that
many CBD products purporting to comply with the Farm Bill may in fact
contain more than 0.3 percent of THC, and therefore, may produce
unexpected positive drug test results.313 As such, the agency has warned
that “CBD use is not a legitimate medical explanation for a laboratoryconfirmed marijuana positive result” and “consumers should beware
purchasing and using” such products.314 Thus, if state law required
DOT-governed employers to cover marijuana through workers’
compensation or health plans and an employee uses marijuana
products, the employee could face negative ramifications, including
termination of employment.315

IV.

Recommendations

To protect residents’ health and safety, states should not enact laws
mandating that health plans and workers’ compensation cover
marijuana. Such laws cannot exist legally until Congress or the FDA
removes marijuana from Schedule I and the FDA creates a new
regulatory pathway for non-FDA-approved cannabis products used for
the treatment of specific conditions. While both Congress and the DEA
have considered de-scheduling marijuana several times over the years,
both have declined to do so.
To the extent that ERISA preempts state law, employers should
voluntarily choose not to cover non-FDA-approved cannabis products
due to the risk of criminal and tort liability, and the various employee
safety and efficacy concerns addressed above. Instead, employers
should only cover FDA-approved products so that their employees have
access to safe and effective drugs. If states pass laws requiring coverage
of non-FDA-approved products, employers could deny coverage and
challenge those laws in court by applying similar legal arguments as
those presented in Bourgoin. Additionally, it is important for employers
to educate their employees on the risks of non-FDA-approved cannabis
311

DOT “Recreational Marijuana” Notice, supra note 309.
DOT “CBD” Notice, supra note 310.
313 DOT “CBD” Notice, supra note 310.
314 DOT “CBD” Notice, supra note 310.
315 DOT employees likely to face discipline include: school bus drivers, truck drivers,
train engineers, subway operators, aircraft maintenance personnel, transit fire-armed
security personnel, ship captains, and pipeline emergency response personnel, among
others. DOT “Recreational Marijuana” Notice, supra note 309.
312
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products so that they are less likely to seek coverage or reimbursement
for such products.

V.

Conclusion

Non-FDA-approved cannabis products pose health and safety risks
to employees and liability risks for employers. Moreover, state laws that
would require employers to cover such products through health plans
or workers’ compensation benefits conflict with, and are preempted by,
federal laws such as the CSA. As such, states should not enact such
mandates.

